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treatment, thereby reducing the difference in treatment 
results among different institutions; (3) to reduce unneces-
sary costs and efforts; (4) help enable people to undergo 
treatment without anxiety.
These guidelines provide only guidance on the indica-
tions for treatment and do not restrict or prohibit the use of 
any treatment deviating from those described herein.
Responsibilities
The Japan Esophageal Society assumes responsibility for 
the content described in these guidelines.
However, responsibility for the treatment results should 
be borne by the doctor providing the treatment and shall 
not rest with the Japan Esophageal Society.
Basic principles adopted for the preparation of these 
guidelines
These guidelines only present indications for the treat-
ment procedures and do not address the technical prob-
lems of each treatment modality. The principles of present-
ing adequate treatment procedures include the following: 
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Introduction
Purpose
These guidelines are intended for doctors who are engaged 
in the diagnosis and treatment of esophageal carcinoma, for 
the following purposes: (1) to present the standard practice 
for the diagnosis and treatment of esophageal carcinoma 
with a high regard for the principles of evidence-based 
medicine (EBM); (2) to improve the safety and results of 
This article originally appeared in Japanese as Shokudo gan 
shindan · chiryo gaidorain (Guidelines for Diagnosis and 
Treatment of Carcinoma of the Esophagus), published by 
Kanehara, Tokyo, April.
This article does not contain any studies with human or animal 
subjects performed by any author(s). This paper consists of 
summary and text of Guidelines for Diagnosis and Treatment 
of Carcinoma of the Esophagus April 2012 edited without 
references and clinical questions and answers and grade of 
recommendation.
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(1) treatments are introduced in relation to the progression of 
carcinoma, without excess or deficiency; (2) the therapeutic 
efficacy is evaluated by evidence-based approaches; (3) the 
final evaluation of treatment procedures is based on the sur-
vival period, but remission of symptoms, reduction of tumor, 
and improvement of quality of life (QOL) are also taken into 
account; (4) evaluation is carried out depending on the loca-
tion of the lesion. We propose to revise these guidelines con-
tinually along with advances in medical science.
Choice of treatment and patients’ consent
When choosing a treatment, regardless of whether it is 
made based on these guidelines or not, it is necessary that 
the doctors explain the details of the treatment, the reasons 
for choosing it, possible complications, treatment results, 
etc., to patients to obtain the patients’ understanding and 
informed consent.
Level of recommendation
“Clinical Questions” are attached to each item, and the lev-
els of evidence/strength of recommendation for each item 
is indicated according to Minds (Medical Information Net-
work Distribution System: http://minds.jcqhc.or.jp/n/) clas-
sification of recommendation grades (A, B, C1, C2, D), 
together with the recommendation grades of the Committee 
to Develop Guidelines for Diagnosis and Treatment of Car-
cinoma of the Esophagus.
Algorithm for treatment of esophageal carcinoma (Fig. 1) 
Epidemiology, present status, and risk factors
Summary
With regard to the dynamic trends of esophageal carcinoma 
in Japan, the incidence rate1 has been increasing slowly in 
men, whereas it has been leveling off in women. The mor-
tality has been leveling off in men, but has been decreasing 
in women.
Currently, among patients with esophageal carcinoma, 
the percentage of males is higher, and the percentage of 
patients in their 60s to 70s is high. The carcinoma is most 
frequently located in the middle thoracic esophagus. Squa-
mous cell carcinoma is the predominant histologic type. 
Esophageal carcinoma is frequently associated with syn-
chronous or metachronous multiple carcinoma. 
The cited risk factors include smoking and alcohol 
drinking in the case of squamous cell carcinoma. In 
regard to the risk factors for adenocarcinoma, Barrett’s 
epithelium derived from persistent inflammation of the 
lower esophagus due to gastroesophageal reflux disease 
(GERD) has been reported to serve as the background 
mucosa for esophageal carcinoma in Europe and North 
America. In Japan, however, the risk associated with 
this factor remains unclear because of the scarcity of 
patients.
Morbidity and mortality
According to statistics issued by the Center for Cancer 
Control and Information, National Cancer Center based on 
cancer morbidity data derived from the Population-Based 
Cancer Registry, the estimated incidence rate in 2004 
(crude incidence rate) was 24.4 persons per 100,000 popu-
lation in men and 4.0 persons per 100,000 population in 
women. The age-adjusted incidence rate2 has been showing 
1
 Incidence rate The number of cases detected in a certain popula-
tion during a certain period of time divided by the number of indi-
viduals in the population. The data shown are those provided by the 
Center for Cancer Control and Information Services, National Cancer 
Center, on the basis of the national statistics of cancer morbidity data 
derived from the Population-Based Cancer Registry (1975–2005).
2
 Age-adjusted incidence rate The incidence rate that would have 
been observed if the composition of the population was the same as 
the base population.
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an upward trend in men, whereas there has been no particu-
lar pattern of increase or decrease recently in women.
According to the vital statistics compiled by the Minis-
try of Health, Labour and Welfare, there were 11,746 
deaths from esophageal carcinoma in 2008 (the crude mor-
tality rate3 9.3 persons per 100,000), which accounted for 
3.4 % of all deaths from malignant neoplasms. The crude 
mortality rate associated with esophageal carcinoma was 
16.3 persons per 100,000 population in men, ranking after 
cancers of the lung, stomach, large intestine, liver, and pan-
creas. The corresponding rate was 2.7 persons per 100,000 
population in women, ranking below the 10th place. The 
age-adjusted mortality rate4 of esophageal carcinoma has 
been leveling off in men and decreasing in women.
Cancer mortality data from vital statistics and vari-
ous graphs based on this data are available at the Center 
3
 Crude mortality rate: The number of deaths occurring during a cer-
tain period of time divided by the population during the period.
4
 Age-adjusted mortality rate The mortality rate that would have 
been observed if the composition of the population was the same as 
the base population. Because the cancer mortality rate increases as 
the age advances, the crude mortality rate increases in a population 
containing a greater proportion of elderly people than in one contain-
ing a smaller proportion of elderly people. Therefore, the mortal-
ity rate in a population as a whole is obtained in a way adjusted for 
the age composition of a population used as the base (base popula-
tion). The 1985 model population (virtual population model based on 
Japan’s population in 1985) is the base population used in Japan.
for Cancer Control and Information Services, National 
Cancer Center (http://ganjoho.jp/professional/statistics/
index.html).
Present status of esophageal carcinoma in Japan
With regard to the present status of esophageal carci-
noma in Japan, a nationwide survey conducted by the 
Japan Esophageal Society (2002) revealed that male 
patients outnumbered female patients, with a male–
female ratio of about 6:1. Most patients were in their 
60s or 70s, accounting for about 68 % of the patients 
overall. The carcinomas were predominantly located 
in the middle thoracic esophagus (51.6 %), followed in 
frequency by the lower thoracic esophagus (24.2 %), 
upper thoracic esophagus (13.4 %), abdominal esopha-
gus (4.5 %), and cervical esophagus (4.0 %). Squamous 
cell carcinoma was the overwhelmingly frequent histo-
logic type, accounting for 92.9 % of all cases, followed 
in frequency by adenocarcinoma (2.4 %). A family his-
tory of malignant tumor was found in 22.7 % of patients. 
A family history of esophageal carcinoma was present 
in 17 % of all cases with a family history of malignant 
tumor, although gastric cancer was the most frequent at 
28.9 %. About 20 % of patients with esophageal carci-
noma have synchronous or metachronous multiple can-
cer, which was the most frequently observed gastric 
cancer, followed by pharyngeal cancer, representing an 
important issue in the clinical diagnosis and treatment of 
Fig. 1  Algorithm for treatment of esophageal carcinoma
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esophageal carcinoma (see “Diagnosis and treatment of 
double carcinoma”).
Risk factors
The risk factors for esophageal carcinoma are alcohol 
drinking and smoking.
Alcohol and smoking are important risk factors 
for squamous cell carcinoma, serving as risk factors 
in more than 90 % of all cases of esophageal carci-
noma in Japan. It is known that the risk of developing 
esophageal carcinoma is increased by concomitant use 
of tobacco and alcohol. In October 2009, a working 
group of the World Health Organization prescribed that 
acetaldehyde associated with alcoholic beverages is a 
Group 1 carcinogen. In addition, in relation to dietary 
factors, poor nutritional status and vitamin deficiency 
due to inadequate intake of fruits and vegetables are 
also reported as risk factors. By contrast, intake of 
green and yellow vegetables and fruits are reported as 
preventive factors.
Although adenocarcinoma accounts for only a small per-
centage of patients with esophageal carcinoma, the percent-
age is increasing in Europe and North America, accounting 
for about more than half of all the cases of esophageal carci-
noma. Barrett’s epithelium caused by persistent inflammation 
of the lower esophagus due to gastroesophageal reflux dis-
ease (GERD) is known to serve as the background mucosa of 
the disease in Europe and America. GERD, high BMI, which 
serves as a risk factor for GERD, and smoking are involved 
in the development of the disease. In Japan, no clear evidence 
has been established because of the scarcity of cases.
Diagnosis of esophageal carcinoma
Diagnosis of the stage of carcinoma
Summary
The clinical stage of esophageal carcinoma is determined 
by various diagnostic imaging procedures in terms of the 
depth of tumor invasion, and presence/absence of lymph 
node metastasis and distant metastasis. Patients should be 
informed of the therapeutic strategies based on the assess-
ment of the characteristic features of the lesion (grade of 
malignancy) and their general condition. Therapeutic strat-
egies should be decided after explaining the basis for and 
process of diagnosis to patients, and obtaining their under-
standing, will, and consent (Fig. 2).
Evaluation of the general condition
Radical surgery for esophageal carcinoma, particularly 
surgery accompanied by thoracolaparotomy, is the most 
invasive among various types of surgery for gastrointes-
tinal carcinomas. Recent advances in surgical techniques, 
anesthetic procedures, postoperative management, etc., 
have led it to safer and more radical treatment for esopha-
geal carcinoma. However, the incidences of postoperative 
complications and surgery-related mortality still remain 
higher than those for other diseases. It should also be noted 
that esophageal carcinoma occurs predominantly in people 
of advanced age, i.e., 65–70 years of age, and that people 
of this age group are more likely to have various lifestyle-
related diseases (hypertension, diabetes mellitus, hyperlipi-
demia, etc.). Therefore, it is desirable that application of 
Fig. 2  Algorithm for deciding 
the therapeutic strategies for 
esophageal carcinoma
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radical surgery be decided with due caution after evalua-
tion of vital organ function. When applying chemotherapy, 
radiotherapy or chemoradiotherapy, it is desirable that the 
functions of vital organs meet certain criteria for imple-
mentation of the therapy.
In this connection, several tests that are required for 
evaluating the general condition and function of major 
organs are described below, in addition to rough guides 
for judging the test results. However, therapy based on the 
patient’s general condition should follow comprehensive 
evaluation and it is not easy to establish accurate numerical 
standards.
Performance status (PS)
Performance status is a simple and useful index commonly 
used for comprehensive evaluation of the patient’s general 
condition (Table 1). Esophageal carcinoma patients with PS 
scores of 0–2, as described below, are generally considered 
as suitable candidates for radical surgery, chemotherapy, or 
radiotherapy.
Pulmonary function tests
Aging and smoking history are risk factors in patients 
with carcinoma of the esophagus, and the prevalence of 
chronic obstructive lung disease is relatively high among 
these patients. Pulmonary function test results are impor-
tant indices for deciding the advisability of thoracot-
omy. Whether or not thoracotomy is indicated should be 
judged comprehensively, taking into account the results of 
spirometry (%VC, FEV1.0 %, %RV/TLC), arterial blood 
gas analysis, chest radiography findings, CT findings, 
smoking history, and past medical history. Thoracotomy 
should be considered carefully if the values of %VC is 
40 % or less, FEV1.0 % is 50 % or less, FEV1.0 is less 
than 1.5 L, and %RV/TLC is 56 % or more, respectively, 
and the arterial oxygen tension is 60 Torr or less.
Cardiac function tests
In principle, surgery is not indicated in patients with heart 
failure due to valvular disease or cardiomyopathy, severe 
arrhythmia, or myocardial infarction within 3 months prior 
to the onset. A resting or exercise electrocardiography 
(ECG) is carried out as a rule. If any abnormality is found, 
the patient should be subjected to Holter ECG monitor-
ing, echocardiography, cardiac catheterization, or exercise 
stress perfusion imaging.
It is desirable to consult with a cardiovascular intern-
ist if the patient has cardiac function abnormalities or has 
been on antiplatelet therapy or anticoagulant therapy before 
surgery.
Hepatic function tests
Surgical treatment is basically not indicated for severe 
hepatitis or fulminant hepatitis. In cases of chronic 
hepatitis or hepatic cirrhosis, surgical treatment should 
be considered based on a comprehensive evaluation of 
blood counts and the results of blood coagulation tests, 
blood biochemistry tests, ICG stress test (15 min), and 
hepatitis screening. Excluding special conditions, sur-
gery is basically not performed in patients who have 
an ICG retention rate of 40 % or more at 15 min due 
to hepatic dysfunction. If the value is 20–40 %, appli-
cation of minimally invasive surgery including reduc-
tion of operative radicality may be considered with due 
caution.
It has been pointed out that systemic chemotherapy 
may cause reactivation of hepatitis B virus in HBs antigen-
positive patients. Chemotherapy may also cause fulminant 
hepatitis in patients who have a history of hepatitis B virus 
infection (negative for HBs antigen and positive for HBc 
antibody or HBs antibody). Therefore, it is desirable to 
consult a hepatologist beforehand.
Renal function tests
Evaluation of renal function includes general urinalysis, 
serum creatinine, BUN, electrolytes, and creatinine clear-
ance (Ccr). Although it is relatively rare for surgery to be 
ruled out only because of renal function deterioration, it is 
desirable to explain to the patient the possible need for dial-
ysis therapy if the serum Cr level is 2.0 mg/dL or more and 
the Ccr is 30 % or less.
Glucose tolerance test
Perioperative blood glucose control should be implemented 
strictly in patients with diabetes or decreased glucose toler-
ance. Measurement of fasting blood glucose levels, the oral 
Table 1  Eastern Cooperative Oncology Group (ECOG) activity score
PS 0 Fully active and able to carry out all pre-disease activities 
without restriction
PS 1 Restricted in physically strenuous activities, but ambulatory 
and able to carry out work of a light or sedentary nature, 
e.g., light housework and office work
PS 2 Ambulatory and capable of all self-care, but unable to carry 
out any work activities. Up and about more than 50 % of 
waking hours
PS 3 Capable of only limited self-care, confined to bed or chair 
more than 50 % of waking hours
PS 4 Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair
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75 g glucose tolerance test, measurement of HbA1c lev-
els, quantitative urinary glucose measurement, and urinary 
ketone testing should be performed. Preoperative control 
is targeted at a fasting blood glucose of <140 mg/dl, daily 
urinary glucose excretion of ≤10 g, and negative test for 
urinary ketones.
Other considerations
Central nervous system function, including the presence/
absence of mental disorders, should be evaluated comprehen-
sively. In general, radical surgery is not indicated for patients 
with carcinoma of the esophagus when there is a concomi-
tant acute-phase cerebrovascular disorder. It is desirable that 
patients with depression, anxiety, delirium, or dementia be 
referred for professional evaluation by a psychiatrist.
Endoscopic treatment
Summary
The mainstay of endoscopic treatment is endoscopic resec-
tion (ER).
Endoscopic resection includes conventional endoscopic 
mucosal resection (EMR), in which the affected mucosa is 
held or aspirated and resected with a snare, and endoscopic 
submucosal dissection (ESD), which refers to en bloc 
resection of an extensive lesion using an IT knife or a hook 
knife. Other available endoscopic treatments include photo-
dynamic therapy (PDT),5 argon plasma coagulation ther-
apy,6 and electromagnetic coagulation therapy.
Indications for endoscopic resection (Fig. 3) Among 
lesions that do not exceed the mucosal layer (T1a), those 
remaining within the mucosal epithelium (EP) or the lam-
ina propria mucosae (LPM) are extremely rarely associated 
with lymph node metastasis; therefore, endoscopic resec-
tion is a sufficiently radical treatment for these lesions. 
Lesions reaching the muscularis mucosae or slightly infil-
trating the submucosa (up to 200 μm, T1b-SM1) are ame-
nable to mucosal resection, but may have a risk of lymph 
node metastasis. Therefore, these cases represent relative 
indications. Furthermore, 50 % of lesions invading deeper 
(more than 200 μm) into the submucosa (T1b-SM2) are 
associated with metastasis, and even superficial carcinomas 
5
 Photodynamic therapy (PDT) In this treatment modality, the 
oncotropic, light-sensitive substance porfimer sodium (Photofrin) 
is injected intravenously, and tumor tissue is necrotized by applying 
630 nm red light to the light-sensitive substance selectively incorpo-
rated into the tumor. Use of this treatment for early carcinomas of the 
lung, stomach, and uterus and superficial esophageal carcinoma has 
been covered by the national health insurance in Japan since October 
1994. The reported local control rate in cases of superficial esopha-
geal carcinoma is 90 %. PDT is reported to be effective for unresect-
able cases by ER and remnant lesions after ER, radiation therapy, or 
chemoradiation therapy.
6
 Argon plasma coagulation (APC) This is an endoscopic treatment 
method in which argon gas is applied, and tissue is cauterized by 
thermocoagulation using high-frequency currents.
Fig. 3  Indications for endoscopic resection
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should be treated in the same manner as advanced carcino-
mas (carcinomas exceeding the muscularis propria).
Mucosal resection covering 3/4 of the entire circumfer-
ence is likely to be associated with postoperative cicatricial 
stenosis. Therefore, sufficient explanation should be given 
to the patient prior to the operation and preventive meas-
ures must be taken. In cases of superficially spreading car-
cinoma, deep infiltration may occur in several areas, neces-
sitating careful diagnosis of the depth of invasion.
Diagnosis of resected tissue specimens There are limita-
tions to all modes of diagnosis of the depth of tumor inva-
sion. It is also difficult to accurately determine the depth 
of invasion of extensive lesions. Thus, tissue specimens 
obtained by en bloc resection are necessary.
Treatment of lesions not amenable to ER Elevation 
of the mucosa may pose difficulty in additional ER of 
lesions remaining marginally after ER or ER after radi-
otherapy or chemoradiotherapy. These cases and cases 
with a bleeding tendency are not amenable to ER, and 
consideration of other treatment options such as photo-
dynamic therapy (PDT) and argon plasma coagulation 
(APC) is required.
Superiority of en bloc resection En bloc resection is 
desirable for histologic diagnosis of resected specimens. 
Endoscopic submucosal dissection (ESD) enables en bloc 
resection of lesions which formerly were subjected to frac-
tional resection. Further development of equipment and 
spread of improved techniques are anticipated.
Complications Various complications, including bleed-
ing, esophageal perforation, and cicatricial stenosis have 
been reported in association with ER, including ESD. The 
need for prevention, prophylactic measures, and treatment 
of these complications should be well recognized. There 
has been extensive discussion on the need for additional 
treatment after diagnosis of resected tissue.
Indications for endoscopic resection
Handling of resected specimens and evaluation of the 
integrity of treatment
The rules for the handling of endoscopically resected speci-
mens and the procedures for histopathological examination 
to help determine therapeutic strategies are as follows:
1. Only specimens obtained by en bloc resection should 
be used for histopathological evaluation of the ade-
quacy of resection.
2. The following procedures should be undertaken when 
handling specimens, in accordance with the Guidelines 
for Clinical and Pathologic Studies on Carcinoma of 
the Esophagus, 10th edition.
• EMR and ESD specimens should be stretched out so 
that they are approximately the same size as in vivo, 
and the proximal and distal ends should be identified. 
Specimens should then be promptly fixed.
• Iodine staining is recommended before sectioning, to 
identify the iodine-unstained area.
• Specimens should be sectioned in a direction that 
allows accurate assessment of the resection margins. 
When the specimen has adequate resection margins, 
it should be sectioned transversely (perpendicular to 
the long axis) to obtain as much information as pos-
sible. When the specimen has small resection margins, 
it should be sectioned perpendicular to the tangent line 
at the smallest margin. The entire specimen should be 
continuously sectioned at 2–3 mm intervals. The cut 
surface should include the full thickness of the epithe-
lium and the muscularis mucosae (Fig. 4).
3. The histopathological diagnosis should be made by 
examination of all the sections obtained by the above 
process.
4. The objective of performing histopathological diagno-
sis of endoscopically resected specimens is to deter-
mine whether any additional treatment is necessary. 
The depth of invasion, presence/absence of lympho-
vascular invasion, and status of the resection margin 
should therefore be specified to determine whether the 




Therapeutic strategies vary according to factors such as the 
location of the esophageal lesion, extent of the lesion, depth 
of invasion, presence/absence of metastasis, general condi-
tion of the patient, and the institution that provides the treat-
ment. There are many treatment options available. Some 
treatments are already formulated and used commonly in 
daily clinical practice. Some other treatments are in the 
clinical research phase and in the process of expanded use, 
although lacking in solid supportive evidence.
With regard to surgical treatment, there are various 
options depending on the institution as to the width of 
the resection margin, extent of lymph node dissection, the 
organ and route used for reconstruction, multimodality 
therapy including adjuvant therapy, and salvage surgery 
following definitive (chemo-) radiotherapy. Therefore, it is 
difficult to choose the currently most appropriate standard 
therapy based on evidence.
The esophagus extends anatomically from the cervical 
through the thoracic region into the abdominal region. It 
8 Esophagus (2015) 12:1–30
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is surrounded by various organs according to its location. 
Although therapeutic strategies vary widely according to 
the location of the tumor, stage, and general condition of 
the patient, surgery remains the mainstay of treatment. In 
general, absolute indications for endoscopic treatment are 
carcinomas with a depth of invasion classified as EP or 
LPM. However, esophagectomy and reconstruction not 
accompanied by lymph node dissection may be indicated 
as a comprehensive judgment for extensive early carcino-
mas without clinical lymph node metastasis. For lesions 
reaching up to the muscularis mucosa, the frequency of 
lymph node metastasis is about 9.3 %. This percentage 
increases as the depth of invasion increases. For lesions 
invading deeper into the submucosal tissue, the rate of 
metastasis is about 50 %. In general, if there is reasonable 
ground for suspecting lymph node metastasis, lymph node 
dissection should be carried out even for superficial lesions 
in the treatment of T2 or deeper carcinomas. Surgery may 
be considered in patients with T4 lesions, only when cura-
tive resection is judged to be applicable. Basically, surgery 
is not chosen as the initial treatment when there is metasta-
sis to distant lymph nodes or other organs.
At present, efforts are focused on the establishment 
of surgical treatments by the formulation and standardi-
zation of surgical techniques represented by three-field 
lymph node dissection (cervical, thoracic, and abdominal) 
for cases of thoracic esophageal carcinoma, as well as the 
introduction and promotion of endoscopic surgery (video-
assisted surgery) based on established surgical treatments 
and minimization of surgical invasion through the use of 
limited surgery. However, supportive evidence to promote 
these actions still remains inadequate.
Surgery for cervical esophageal carcinoma
Summary The anatomical structure and physiological 
functions of the hypopharynx to the cervical esophagus are 
complicated. Because the loss of vocal function by com-
bined laryngectomy greatly affects the postoperative QOL 
of the patient, the surgical procedure should be determined 
carefully, after due consideration given to the balance 
between the radicality of the treatment and the QOL.
Resection
Carcinoma of the cervical esophagus is often advanced 
at diagnosis, with a high incidence of lymph node metas-
tasis and infiltration into other organs. However, lymph 
node metastasis is mainly restricted to the cervical region, 
and radical surgery is often applicable. Patients who have 
extensive distant metastases and metastasis to a number of 
superior mediastinal lymph nodes are usually not suitable 
candidates for radical resection.
Larynx-conserving surgery
This operation is indicated for patients in whom the 
tumor has not invaded the larynx or trachea and in whom 
the proximal end of the tumor remains inferior to the 
esophageal orifice.
Larynx-conserving surgery is divided into larynx-con-
serving cervical esophagectomy and larynx-conserving 
total esophagectomy according to the necessity for thoracic 
esophagectomy. Concomitant resection of the thoracic 
Fig. 4  Sectioning of specimens obtained by endoscopic resection. The specimen should be cut after the iodine-unstained area is identified by 
the staining
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esophagus may be performed when the tumor has invaded 
the thoracic esophagus, when there are multiple lesions not 
amenable to endoscopic resection, or when it is difficult 
to perform reconstruction requiring microvascular anasto-
mosis. This surgery may be indicated for patients in whom 
preoperative therapy results in tumor shrinkage.
Laryngopharyngoesophagectomy (combined laryngectomy)
Laryngopharyngoesophagectomy is indicated for 
patients with tumors invading the larynx, trachea, and 
hypopharynx, or those in whom sufficient preservation of 
the cervical esophagus to perform anastomosis is difficult.
This type of surgery is divided into laryngopharyngec-
tomy plus cervical esophagectomy and laryngopharyngec-
tomy plus total esophagectomy according to the neces-
sity for thoracic esophagectomy. Resection of the thoracic 
esophagus may be combined when the tumor has invaded 
the thoracic esophagus, when there are multiple lesions 
not suitable for endoscopic resection, or when it is dif-
ficult to perform reconstruction requiring microvascular 
anastomosis.
Lymph node dissection
According to the 10th edition of the Japanese Classifica-
tion of Esophageal Cancer, cervical lymph nodes include 
superficial cervical nodes of the neck [100], cervical parae-
sophageal lymph nodes [101], deep cervical lymph nodes 
[102], peripharyngeal lymph nodes [103], and supraclav-
icular lymph nodes [104]. The major thoracic lymph nodes 
are the recurrent laryngeal nerve lymph nodes [106-rec] 
and upper thoracic paraesophageal lymph nodes [105].
Among these, [101] and [106-rec] lymph nodes belong 
to group 1, and [102], [104] and [105] lymph nodes belong 
to group 2 in cases of cervical esophageal carcinoma. It is 
preferable to remove them.
Method of reconstruction
Although reconstruction using a free intestinal graft is 
common when the operation involves cervical manipula-
tion alone, gastric tube reconstruction may be employed 
in some cases. Myocutaneous flaps or skin rolls may also 
be used for reconstruction. When concomitant thoracic 
esophagectomy is performed, the stomach or colon is used 
for reconstruction as in cases of usual reconstruction fol-
lowing resection of the thoracic esophageal carcinoma. 
However, a free jejunal graft may be added if the length of 
the organ prepared for reconstruction is not sufficient.
Surgery for thoracic esophageal carcinoma
Summary Thoracic esophageal carcinoma is often accompa-
nied by extensive lymph node metastasis in the cervical, tho-
racic, and abdominal regions. A right thoracotomy with total 
extirpation of the thoracoabdominal esophagus and lymph 
node dissection is generally carried out. The width of the resec-
tion margin of the tumor should be decided bearing in mind 
both the possibility of persistent carcinoma in the remaining 
esophageal wall and the extent of lymph node dissection.
In cases of thoracic esophageal carcinoma, the extent of 
lymph node dissection should be determined after preop-
erative evaluation of the location, size, and depth of inva-
sion of the carcinoma by imaging modalities including 
computed tomography (CT), magnetic resonance imaging 
(MRI), and PET.
Three routes of reconstruction, i.e., antethoracic, retros-
ternal, and posterior mediastinal are available. Although 
each of these routes has its own advantages and disadvan-
tages, the posterior mediastinal route has been most fre-
quently employed recently. The stomach is the most com-
mon organ used for reconstruction.
Resection
Thoracic esophageal carcinoma is often accompanied by 
extensive lymph node metastasis in the cervical, thoracic, 
and abdominal regions. A right thoracotomy with total 
extirpation of the thoracoabdominal esophagus, and lymph 
node dissection of the lymph nodes in all the three regions 
(cervical, thoracic, and abdominal) is generally carried out.
The width of the margin of resection of the tumor should 
be decided bearing in mind both the possibility of persis-
tent carcinoma in the remaining esophageal wall and the 
extent of lymph node dissection. Persistent carcinoma in 
the esophageal wall may result from intramural spread, 
intraepithelial spread, vascular invasion, or intramural 
metastasis. Submucosal spread increases according to the 
tumor depth, reportedly reaching 30 mm in cases of T2 
carcinoma. There is no standard extent of resection estab-
lished for all of the above cases, and a sufficient margin 
may not be available at the proximal end of the resection 
according to the location of the tumor. Thus, the extent of 
resection should be decided on the basis of the findings 
on preoperative esophagography and endoscopy, intraop-
erative rapid frozen-section diagnosis, and intraoperative 
macroscopic evaluation including close observation of the 
mucosal surface (and iodine application) under intraopera-
tive esophagotomy.
Endoscopic esophagectomy and reconstruction
Thoracoscopy- or laparoscopy-assisted esophagectomy 
with esophageal reconstruction and mediastinoscopy- or 
laparoscopy-assisted transhiatal esophagectomy have been 
reported as promising surgical procedures, although they 
are still in the investigational stages, in view of the mini-
mal invasiveness, radicality, and the long-term results. 
In Japan, endoscopic esophagectomy is almost always 
performed as a radical surgery which includes sufficient 
lymph node dissection comparable to open surgery. Indi-
cations for this operation vary among institutions and 
it is used for T3 cancer in some institutions. It has been 
reported that endoscopic esophagectomy is comparable 
to conventional standard surgery with open thoracotomy 
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in terms of the operating time, amount of blood loss, and 
number of dissected lymph nodes, and is advantageous in 
terms of providing early relief from postoperative pain and 
rapid restoration of vital capacity, as long as it is carried 
out at institutions with accumulated clinical experience. 
On the negative side, recurrent laryngeal nerve paralysis is 
reported to occur more frequently after this procedure than 
after standard surgery via thoracotomy.
Some techniques have been suggested for performing 
carrying out implementing safe endoscopic surgery with 
reduced operating time and improved accuracy of node dis-
section. These techniques include for direct manipulations, 
via a minor thoracotomy, video-assisted thoracoscopic sur-
gery (VATS) with minor thoracotomy and hand-assisted 
laparoscopic surgery (HALS), involving manipulation with 
one hand on the abdomen. Although thoracic manipula-
tions have been predominantly carried out with the patient 
in the left lateral decubitus position, complete endoscopic 
thoracic manipulations with the patient in the prone position 
is becoming more and more frequent recently. Transhiatal 
esophagectomy with mediastinal dissection using a medias-
tinoscope inserted via a cervical incision or with mediasti-
nal dissection via laparotomy has also been proposed. It is 
reported that endoscopic surgery allows node dissection with 
improved accuracy because of the higher-power visualiza-
tion that allows observation of microanatomy. However, no 
definitive conclusions have been reached yet as to the long-
term outcomes of this form of surgery as compared to those 
of conventional standard surgery with open thoracotomy and 
node dissection, and further investigation in randomized con-
trolled trials is awaited.
Lymph node dissection
Thoracic esophageal carcinoma is commonly accom-
panied by lymph node metastasis in extensive areas from 
the cervical to the abdominal region. However, because the 
distribution and incidence of lymph node metastasis vary 
according to the location, size, and depth of invasion of the 
tumor, preoperative evaluation of individual patients by CT, 
US, MRI, and PET is important to determine the extent of 
lymph node dissection.
Radical surgery for thoracic esophageal carcinoma 
is accomplished ordinarily as a combination of three 
approaches, i.e., the cervical, thoracic, or abdominal 
approaches. The mediastinal approach has also been pro-
posed as an alternative to the cervical approach for dissec-
tion of the cervical paraesophageal lymph nodes [101].
Upper thoracic esophageal carcinoma (Ut)
Patients with this type of lesion usually present with 
lymph node metastasis, mainly in the cervical to upper 
mediastinal region; thus, lymph node dissection should 
include the cervical region. Addition of median sternot-
omy or manubriotomy has also been suggested to allow a 
better field of view of the cervicothoracic junction region. 
Although metastasis to the lower mediastinal or abdominal 
lymph nodes occurs less frequently in cases of Ut, dissec-
tion should ordinarily cover all the three regions, i.e., cervi-
cal, thoracic, and abdominal regions, including the left gas-
tric artery lymph nodes.
Middle thoracic esophageal carcinoma (Mt)
In general, metastatic lymph nodes in cases of Mt are 
relatively evenly distributed over the cervical to upper, mid-
dle, and lower mediastinal and abdominal regions. Because 
the involvement of cervical lymph nodes other than the 
cervical paraesophageal lymph nodes [101] is relatively 
rare, lymph node dissection via the intrathoracic approach 
instead of the cervical approach has also been proposed.
When the thoracic approach is judged to be inadequate 
based on the preoperative diagnosis of metastasis, it is 
important to add a cervical approach to dissect the lymph 
nodes surrounding the bilateral recurrent laryngeal nerve up 
to the inferior pole of the thyroid. In particular, the lymph 
nodes of 101L are difficult to be dissected thoroughly by 
thoracic manipulations alone, and additional dissection via 
a cervical incision is necessary. In addition, supraclavicular 
lymph nodes [104] cannot be dissected by thoracic manip-
ulations, and a cervical approach is necessary for secure 
lymph node dissection in this region.
Lower thoracic esophageal carcinoma (Lt)
In cases of Lt, while lymph node metastasis mainly 
occurs in the mediastinal and abdominal regions, metasta-
sis to the cervical lymph nodes may also occur, albeit at 
a lower frequency. The optimal approach for lymph node 
dissection remains under discussion; while some pro-
pose adding the cervical approach, similar to the case for 
Mt, others regard the thoracic approach as being superior. 
Because metastasis to the upper mediastinal lymph nodes 
is less frequent in cases of superficial carcinoma of the 
lower thoracic esophagus, there is a view that the extent of 
lymph node dissection could be minimized and that cervi-
cal lymph node dissection could be omitted altogether in 
some cases.
Method of reconstruction (Table 2)
Route of reconstruction
Three routes, i.e., the antethoracic, retrosternal, and pos-
terior mediastinal (including intrathoracic) routes, are avail-
able for reconstruction. The route employed varies accord-
ing to the case, and each route has its own advantages and 
disadvantages. Recently, the posterior mediastinal route 
is the most frequently used for reconstruction when high 
intrathoracic anastomosis is included. Because surgery for 
second primary cancer in the gastric tube is difficult after 
reconstruction via the posterior mediastinal route, the risk 
of carcinoma occurring in the gastric tube should be con-
sidered particularly when long survival is expected.
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Organs used for reconstruction
Reconstruction using the stomach is the most common 
method. In patients with past history of gastrectomy, those 
with a concomitant gastric carcinoma, and those in whom 
the stomach needs to be preserved, colic and ileocolic or 
jejunal grafts may be used.
Anastomosis
Anastomosis may be divided into cervical and intratho-
racic depending on the site of anastomosis. This site of 
anastomosis is chosen according to the location of the 
tumor, the organ used for reconstruction, and the route of 
reconstruction. Intrathoracic anastomosis is associated with 
a high risk of serious complications in the event of anasto-
motic leakage. The anastomosis techniques include manual 
suture and mechanical suture. For intrathoracic anastomo-
sis, mechanical suture using a circular stapler is frequently 
employed. Because anastomotic leakage and stricture exert 
a strong influence on the postoperative course and QOL of 
the patient, it is important to use appropriate anastomotic 
techniques tailored to individual patients.
Surgery for carcinoma of the esophagogastric junction 
(abdominal esophageal carcinoma)
Summary Similar to the case for surgical treatment of 
thoracic esophageal carcinoma, various techniques are 
available for the surgical treatment of carcinoma of the 
esophagogastric junction (E, EG). These include a right 
thoracotomy with dissection including the upper medias-
tinal lymph nodes and reconstruction using a gastric tube, 
lower esophagectomy with proximal gastrectomy or lower 
esophagectomy with total gastrectomy via left thoracolapa-
rotomy or serial left thoracic and abdominal incisions, and a 
transhiatal approach to the lower mediastinum without thor-
acotomy. Metastasis involving the lower paraesophageal to 
upper abdominal lymph nodes is frequent in these cases. 
The most commonly employed technique is intrathoracic 
anastomosis using a gastric tube or the jejunum.
Resection and lymph node dissection
The 10th edition of the Japanese Classification of Esoph-
ageal Cancer defines the esophagogastric junction region 
as the region within 2 cm above and below the esophago-
gastric junction, and esophagogastric junction carcinoma 
as that with its center located within this region. Accord-
ing to this definition, abdominal esophageal carcinoma 
is included in this category. In cases of esophagogastric 
junction carcinoma extending more to the esophageal side 
than to the gastric side (E, EG), right thoracotomy with 
dissection including the upper mediastinal lymph nodes 
and reconstruction using a gastric tube are frequently per-
formed in the same manner as for cases of thoracic esopha-
geal carcinoma. In some cases, lower esophagectomy with 
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gastrectomy via left thoracolaparotomy or serial left tho-
racic and abdominal incisions may be carried out, consider-
ing that cervical or upper mediastinal lymph node dissec-
tion is of lesser significance. A transabdominal approach to 
the lower mediastinum via dilated esophageal hiatus with-
out thoracotomy is also reported. Metastasis to the lower 
thoracic paraesophageal lymph nodes [110], cardiac lymph 
nodes [1] [2], lesser curvature lymph nodes [3], left gastric 
artery lymph nodes [7], and celiac artery lymph nodes [9] 
is frequent.
In cases of esophagogastric junction carcinoma extend-
ing more to the gastric side than to the esophageal side 
(G, GE), metastasis to the mediastinal lymph nodes is less 
frequent; thus dissection of these lymph nodes is of lesser 
consequence. Therefore, these lymph nodes are classified 
as group 3 in the 10th edition of the Japanese Classification 
of Esophageal Cancer.
Method of reconstruction
Intrathoracic anastomosis using a gastric tube, jejunal 
interposition by elevation of the jejunum, and intratho-
racic anastomosis by the Roux-en-Y style are available. 
In cases of esophagogastric anastomosis following lower 
esophagectomy with proximal gastrectomy, postoperative 
reflux esophagitis is a potential problem and may require 
prophylactic measures.
Other surgical treatments
Summary Although radical surgery for esophageal carci-
noma basically consists of resection, lymph node dissec-
tion, and reconstruction, other treatments may be carried 
out if it is difficult or unnecessary to complete these pro-
cedures because of various factors such as the stage and 
malignancy grade of the carcinoma and the general con-
dition of the patient. Transhiatal esophagectomy has been 
performed as a radical operation for mucosal carcinoma or 
abdominal esophageal carcinoma that is difficult to treat 
with an endoscopic procedure and that presumably requires 
no mediastinal lymph node dissection. This has also been 
used as a palliative operation for patients who are not suit-
able candidates for thoracotomy and mediastinal lymph 
node dissection because of poor pulmonary function or 
other reasons. However, indications for this procedure have 
recently become limited because of the expanding applica-
tion of endoscopic treatment as esophagus-preserving ther-
apy and the spread of multidisciplinary therapy including 
chemoradiotherapy.
Bypass surgery may be performed as a palliative treat-
ment for patients who have difficulty in oral intake because 
of esophageal stenosis due to esophageal carcinoma or 
changes after treatment for esophageal carcinoma. How-
ever, the indications for bypass surgery have become lim-
ited because of the spread of esophageal stenting.
Transhiatal esophagectomy
In this method, the thoracic esophagus is detached and 
removed via the cervical and abdominal approaches with-
out thoracotomy. This technique was first reported by 
Turner in 1933. Akiyama et al. introduced this method in 
Japan in 1971, and it has since come to be used widely in 
clinical practice in this country. This technique has been 
employed for resection and reconstruction in patients with 
cervical esophageal carcinoma, patients with thoracic or 
abdominal esophageal carcinoma who are not suitable can-
didates for thoracotomy because of severe pleural adhe-
sions or poor pulmonary function, patients of advanced 
age, and patients with mucosal carcinoma not requiring 
lymph node dissection. Although this technique allows dis-
section of the abdominal to lower mediastinal lymph nodes 
to some extent, upper to middle mediastinal dissection is 
difficult.
Currently, the use of transhiatal esophagectomy has 
become rare because of the spread of chemoradiotherapy 
and endoscopic submucosal dissection.
Treatments for unresectable cases
Advanced esophageal carcinomas that are unresectable 
because of infiltration into other organs or distant metas-
tasis are initially treated by radiotherapy, chemotherapy, 
or chemoradiotherapy. However, patients with esophageal 
stenosis or trachea–esophageal fistula not responding to 
these treatments suffer from difficulty in oral intake, result-
ing in a marked decrease in QOL. Bypass surgery is a pal-
liative treatment used to achieve oral feeding in these cases 
of malignant esophageal stenosis or obstruction. Currently, 
indications for bypass surgery have become rare because of 
the spread of covered esophageal stent placement.
In bypass surgery, the thoracic esophagus is excluded 
from the continuity of the digestive tract and a new route 
of oral intake is made. The route of bypass is antethoracic 
or retrosternal. Because most patients have advanced car-
cinoma and a poor nutritional status, anastomotic leakage 
occurs frequently, necessitating caution. In recent years, 
this procedure has been also employed as a palliative oper-
ation in patients in whom major lesions are judged to be 
unresectable during salvage surgery following definitive 
chemoradiotherapy.
Perioperative management and clinical path
Summary It was previously considered that introduction 
of the clinical path method would be difficult for periop-
erative management of esophageal carcinoma, because of 
the pathological features of this carcinoma and the diver-
sity of surgical techniques available. In recent years, how-
ever, a clinical path for resection and reconstruction of the 
esophagus has been proposed by various institutions and 
has been applied in clinical practice. However, there has 
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been only limited data from large-scale clinical studies 
evaluating the usefulness of a clinical path for periopera-
tive management.
In recent years, an increasing number of institutions 
have included nutritional support teams (NST) for perio-
perative nutritional management of patients with esopha-
geal carcinoma, facilitating early implementation of enteral 
nutrition. As an element of perioperative management, ster-
oid administration is useful and recommended in postop-
erative management. Abstinence from smoking, respiratory 
physical therapy, and preoperative oral care are generally 
considered to be important for the prevention of postopera-
tive complications.
Introduction of a clinical path in perioperative manage-
ment of esophageal carcinoma
Clinical path is a treatment plan prepared to facilitate 
provision of safe team-approached medical care involv-
ing health-care professionals from multiple medical 
fields, including doctors, nurses, pharmacists, nutrition-
ists, and physical therapists, with the aim of improving 
the quality of care through standardization of health care. 
In the USA, along with the introduction of the diagnosis-
related group/prospective payment system (DRG/PPS) 
in 1983, the fixed charge system, replacing the fee-for-
service system, came to be employed for inpatient hos-
pital care and a clinical path was introduced mainly for 
the purpose of reducing the length of stay in the hospi-
tal of patients and to reduce health-care costs. In Japan, 
around the time of the introduction of the diagnosis pro-
cedure combination (DPC) system, clinical paths were 
introduced for the treatment of various diseases in the 
1990s. The use of clinical paths has recently come to be 
considered to be important not only for improvement of 
the quality of health care and medical education to pro-
vide safe team health care, but also for enhancement of 
patient-centered health care, including promotion of 
obtainment of informed consent.
In patients with esophageal carcinoma, the general con-
dition is greatly affected by the disease state and surgery. 
Perioperative management techniques in these patients, 
including the treatment of concomitant diseases, are 
diverse, with large differences among institutions. There-
fore, preparation of a simple clinical path has been consid-
ered to be difficult, as reflected by the scarcity of reports 
documenting the clinical usefulness of a clinical path. The 
various clinical paths for esophageal carcinoma reported 
to date are those developed by institutions to achieve safe 
perioperative management of patients undergoing resection 
and reconstruction of the esophagus. It is currently difficult 
to find evidence comparing the usefulness of clinical paths.
Clinical paths for diagnosis and treatment involving 
EMR and ESD, endoscopic treatment procedures for early 
esophageal carcinoma have already been developed and are 
in clinical use in many institutions. Clinical paths have also 
been introduced for thoracoscopy- or laparoscopy-assisted 
esophagectomy with reconstruction, which are used in 
high-volume centers treating a large number of patients.
Perioperative nutritional management of esophageal 
carcinoma
Nishi et al. have reported that spontaneous healing of 
anastomotic leakage after surgery for esophageal car-
cinoma requires a caloric intake of at least 45 kcal/kg/
day, and that the serum albumin concentration must be 
maintained at 3.5 g/dL or more. It has been reported that 
enteral nutrition in the perioperative period is associated 
with a lower incidence of perioperative complications, due 
to reduced production of endotoxins and inflammatory 
cytokines, as compared to parenteral nutrition. In cases of 
radical surgery for esophageal carcinoma, perioperative 
management by aggressive use of enteral nutrition has been 
reported to be helpful.
In patients undergoing radical surgery for esophageal 
carcinoma, the digestive and absorptive capability of the 
small intestine is often maintained in a normal condition. 
Therefore, it has been considered that early enteral nutrition 
rather than central venous nutrition is desirable to enhance 
postoperative immunity, etc. An enteral feeding tube should 
be placed during surgery, and a liquid diet should be initi-
ated by 1–3 days after surgery.
Salvage surgery
Summary The definition of salvage surgery is often 
debated. In the narrow sense, salvage surgery is aimed at 
curative resection of residual or recurrent tumor after defini-
tive chemoradiotherapy. In Japan, the experience of salvage 
surgery began to be reported in the early 2000s. Although 
its indication and role have not yet been established, sal-
vage surgery is recognized to pose a greater risk than gen-
eral surgery for esophageal carcinoma. It is also known that 
the frequency of noncurative resection is high, resulting in 
a poor prognosis. In contrast, cases of curative resection 
are accompanied by an improved prognosis. Currently, no 
treatment other than salvage surgery (including endoscopic 
resection) is accepted as curative treatment for residual or 
recurrent tumor. Salvage surgery must be implemented 
only with the informed consent of the patients obtained 
after explaining the risks and long-term outcomes, and thus 
requires cautious consideration.
Definition
The 10th edition of the Japanese Classification of 
Esophageal Cancer defines salvage surgery as that for 
residual or recurrent cancer after definitive (chemo-) radi-
otherapy. The variety of surgeries include resection of the 
esophagus, removal of lymph nodes (dissection), and endo-
scopic resection (for salvage endoscopic treatment, see 
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XI. Chemoradiotherapy). Additional resection of residual 
or recurrent tumor after endoscopic treatment may also be 
referred to as salvage surgery, but this is not included in 
these guidelines.
The standard radiation dose for definitive chemora-
diotherapy is 50.4 Gy in Europe and North America, on the 
basis of the results of the INT0123 study. However, in Japan, 
many institutions use 60 Gy or more as the radiation dose for 
definitive chemoradiotherapy. The Japan Esophageal Society 
defines surgery following irradiation of 50 Gy or more as sal-
vage surgery. Although salvage surgery is aimed at achieving 
curative resection, it ends up in non-curative resection at times 
because of its nature as a rescue treatment. Therefore, curativ-
ity (i.e., R0 resection or not) is not included in its definition.
Indications
The indication for salvage surgery is determined by both 
tumor factors and patient factors. Tumor factors include the 
feasibility of radical resection and the long-term prognosis, 
whereas patient factors include the patient’s general abil-
ity to tolerate surgery, especially the functions of important 
organs such as the heart and lung.
The incidence of complications is higher in cases of sal-
vage surgery than in patients treated by surgery alone or 
surgery combined with preoperative chemoradiotherapy 
(radiation dose less than 50 Gy). The reported incidence of 
respiratory complications such as pneumonia is 9–62 %, 
while that of anastomotic leakage is 14–39 %. In particu-
lar, it is of great concern that the incidence of serious com-
plications due to tissue ischemia, such as tracheal necrosis, 
perforation, and necrosis of the reconstructed gastric tube, 
is higher after salvage surgery than that after usual surgery. 
The reported in-hospital mortality after salvage surgery is 
7–22 %, indicating that this type of surgery is associated 
with a higher surgical risk than usual surgery. The high 
incidence of complications and high in-hospital mortality 
should be taken into account when considering the indica-
tions for salvage surgery.
With regard to the postoperative survival rate, the 
reported 5-year survival rate is 25–35 %. Long-term survival 
can be expected in patients only when curative resection is 
achieved. However, the rate of non-curative resection is high 
in salvage surgery, reported to be in the range of 12–50 %. 
Because the prognosis of patients with non-curative resec-
tion is extremely poor, careful judgment is required when 
determining the indications for salvage surgery.
Neoadjuvant therapy
Summary
Neoadjuvant therapy (preoperative adjuvant therapy) 
has been compared with surgery alone or postoperative 
adjuvant therapy in cases of resectable Stage II or III tho-
racic esophageal carcinoma. The significance of neoadju-
vant therapy for Stage I esophageal carcinoma has yet to be 
evaluated.
Neoadjuvant chemotherapy The randomized con-
trolled trial (JCOG9907 study) that compared neoadju-
vant chemotherapy and postoperative chemotherapy with 
cisplatin + 5-FU in patients with resectable Stage II or 
III thoracic esophageal carcinoma (2002 UICC classifica-
tion) revealed a significant improvement in the overall sur-
vival time in the patients given neoadjuvant chemotherapy. 
Based on this finding, neoadjuvant chemotherapy + radical 
surgery for resectable Stage II or III thoracic esophageal 
carcinoma was positioned as a standard treatment in Japan.
Neoadjuvant chemoradiotherapy The results of a meta-
analysis of randomized controlled trials performed in 
Europe and North America have indicated that neoadjuvant 
chemoradiotherapy combined with surgery has the poten-
tial to improve the long-term survival in patients undergo-
ing surgical resection for esophageal carcinoma as com-
pared to surgery alone. In Japan, this combination therapy 
is administered to patients with locally advanced carcinoma 
in some institutions, although, currently, there is no firm 
basis for its recommendation.
An expected advantage of neoadjuvant therapy over post-
operative adjuvant therapy is that it is easier to complete the 
protocol treatment when applied as neoadjuvant therapy. 
Neoadjuvant therapy is expected to improve the resection 
rate and long-term follow-up results by reducing the size of 
the primary lesion and controlling lymph node metastasis 
and micrometastasis. It is possible that neoadjuvant therapy 
allows assessment of the patients’ response to chemotherapy 
and radiotherapy to some extent by allowing histopatho-
logic studies of the resected specimens. However, issues 
of concern include the following: drug resistance may be 
induced; local control may be delayed in ineffective cases, 
resulting in facilitation of metastatic spread of the disease; 
preoperative radiotherapy may make surgical manipulations 
more difficult and increase the postoperative risk.
The multicenter clinical study JCOG9907 carried out 
by the Esophageal Oncology Group of the Japan Clinical 
Oncology Group (JCOG) deserves special mention in the 
present revision of the guidelines, because its results pro-
vided the rationale for neoadjuvant chemotherapy to be 
established as the standard treatment for patients with no 
particular impediments to this treatment.
Neoadjuvant chemotherapy
A number of randomized controlled trials have been con-
ducted in Europe and America addressing the possible ben-
eficial effects of neoadjuvant chemotherapy on the survival 
rates of patients with esophageal carcinoma. According 
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to the results of a meta-analysis of these randomized con-
trolled trials, the effects of neoadjuvant chemotherapy on 
the survival of the patients varied according to the set end 
points. Therefore, the effects of neoadjuvant chemotherapy 
in resectable cases have not yet been established (T1-3N0, 
1M0, UICC Classification, the 2002 edition).
The 2007 Guidelines for Diagnosis and Treatment of 
Carcinoma of the Esophagus recommended the imple-
mentation of neoadjuvant chemotherapy particularly in 
patients with positive lymph node metastasis, on the basis 
of the results of the JCOG9204 study (1992–1997: post-
operative adjuvant chemotherapy with cisplatin + 5-FU 
vs. surgery alone). At the time of revising the guide-
lines, the timing of adjuvant chemotherapy with cis-
platin + 5-FU was examined in the JCOG9907 study 
(1999–2006), and it was found that neoadjuvant chemo-
therapy yielded significantly improved overall survival in 
comparison to postoperative chemotherapy. Therefore, in 
Japan, neoadjuvant chemotherapy with cisplatin + 5-FU 
followed by radical surgery is now regarded as the stand-
ard treatment for resectable Stage II or III thoracic esoph-
ageal carcinoma.
Neoadjuvant chemoradiotherapy
Neoadjuvant chemoradiotherapy is a treatment strategy 
premised on planned surgery and is distinguished from 
rescue treatment for residual or recurrent carcinoma fol-
lowing chemoradiotherapy aimed at radical cure. In recent 
years, this type of treatment is recognized as a tri-modality 
therapy involving a combination of chemotherapy, radio-
therapy, and surgery rather than as neoadjuvant chemoradi-
otherapy. In some cases, a radiation dose of 50.4 Gy, which 
is the standard dose for definitive chemoradiotherapy, is 
used.
In Europe and North America, a number of rand-
omized controlled trials that verified the usefulness of 
neoadjuvant chemoradiotherapy have been reported since 
the latter half of the 1980s, because of the limitations of 
local control by surgery. Although neoadjuvant chemora-
diotherapy did not contribute to overall survival in most 
of these studies, the pCR rate was generally higher in 
patients given neoadjuvant chemoradiotherapy. In addi-
tion, in a study of esophageal adenocarcinoma reported by 
Walsh et al. and in the CALGB9781 study, the postopera-
tive survival rate was significantly higher in patients given 
neoadjuvant chemoradiotherapy than in those undergoing 
surgery alone. In a randomized controlled trial conducted 
by Bosset et al. in patients with squamous cell carcinoma, 
neoadjuvant chemoradiotherapy significantly improved 
the recurrence-free survival period, although there was 
no prolongation of overall survival. Many other rand-
omized controlled trials have demonstrated prolongation 
of survival in patients receiving neoadjuvant chemoradio-
therapy, although there was no significant influence in the 
overall survival rate.
According to a meta-analysis that addressed surgery 
preceded by neoadjuvant chemoradiotherapy vs. sur-
gery alone, when the 3-year survival rate was used as an 
end point, neoadjuvant chemoradiotherapy (20–45 Gy) in 
patients with resectable carcinoma was associated with a 
significant increase in operation-related mortality within 90 
postoperative days. However, it resulted in a decrease in the 
local recurrence rate and significant increase of the 3-year 
survival rate.
In meta-analyses carried out so far in Europe and North 
America, the patient characteristics (histologic type, stage, 
etc.) and chemoradiotherapy protocols have not been con-
sistent. The radicality of surgery has been suggested to 
greatly influence the outcome. No randomized controlled 
trials of neoadjuvant chemoradiotherapy have been carried 
out to date in Japan, and thus at present there is no satisfac-




Surgery combined with postoperative adjuvant therapy has 
been compared to surgery with or without preoperative 
adjuvant therapy in resectable cases or cases of Stage II 
or Stage III thoracic esophageal carcinoma judged as can-
didates for curative resection. However, to date, the value 
of postoperative adjuvant therapy for patients with Stage I 
esophageal carcinoma has not yet been studied.
Postoperative chemotherapy: A randomized controlled 
trial (JCOG9204 study) comparing surgery with and 
without postoperative chemotherapy (cisplatin + 5-FU, 2 
courses) carried out in Japan demonstrated that postopera-
tive chemotherapy resulted in a significant increase in the 
disease-free survival rate as compared to surgery alone, 
although there was no significant difference in the overall 
survival rate. Analysis of subgroups from the JCOG9204 
study demonstrated that the recurrence-preventive effect 
of 2 courses of cisplatin + 5-FU therapy administered 
postoperatively was observed only in patients with posi-
tive lymph node metastasis. Therefore, in clinical practice, 
postoperative adjuvant chemotherapy has been considered 
only after carefully considering the pathological diagnosis 
after radical surgery. However, in view of the results of the 
aforementioned JCOG9907 study, implementation of neo-
adjuvant chemotherapy has been positioned as a standard 
treatment after taking into account the general condition of 
the patient.
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Postoperative radiotherapy: The results of a rand-
omized controlled trial of pre- and postoperative radio-
therapy vs. postoperative radiotherapy alone carried out 
by the Esophageal Oncology Group of the JCOG showed 
that the overall survival rate was significantly higher in 
patients given postoperative radiotherapy alone when 
the analysis was focused only on eligible patients who 
received treatment according to the protocol. Based on 
this finding, preventive postoperative irradiation was for-
merly in wide use in Japan. However, in overseas rand-
omized controlled trials that compared surgery with and 
without postoperative irradiation (usual fractionation; 
45–60 Gy), postoperative irradiation was associated 
with a decrease in the local recurrence in the irradiated 
area, but without a significant increase in the survival 
rate. Therefore, there is little evidence for recommend-
ing postoperative irradiation after curative resection as a 
standard treatment. At present, the significance of postop-
erative (chemo-) radiotherapy is unclear. (Chemo-) radio-
therapy has been employed in clinical practice and also 
reported to be effective in cases of non-curative resection 
or postoperative local recurrence. Although there is insuf-
ficient evidence, some local therapy may be necessary for 
patients who have undergone non-curative resection and 
who have macroscopic residual tumor without distant 
metastasis. (Chemo-) radiotherapy seems to be a useful 
treatment option for such patients.
The rationale for implementing postoperative adjuvant 
therapy is its potential to control local residual tumor after 
surgical resection, lymph node metastasis outside the dis-
section area, and distant micrometastasis, and thereby to 
lead to improvement in long-term outcomes. The advan-
tage of postoperative adjuvant therapy is that it is possible 
to implement treatment suited to the disease stage as deter-
mined at surgery. However, its disadvantages are that the 
absence of evaluable lesions makes it difficult to determine 
its efficacy and postoperative adjuvant therapy may be 
associated with a lower rate of completion of therapy than 
preoperative adjuvant therapy.
The 2007 Guidelines for Diagnosis and Treatment of 
Carcinoma of the Esophagus stated that radical resection 
followed by postoperative chemotherapy was the most 
commonly employed treatment strategy in Japan. How-
ever, preoperative chemotherapy (neoadjuvant chemo-
therapy) is now regarded as a standard treatment on the 
basis of the results of the aforementioned JCOG9907 study 
(1999–2006: neoadjuvant chemotherapy vs. postoperative 
chemotherapy).
Postoperative chemotherapy
In a randomized controlled trial (JCOG8806) in patients 
with squamous cell carcinoma carried out by the 
Esophageal Oncology Group of the JCOG (comparison 
between surgery plus 2 courses of postoperative cispl-
atin + vindesine and surgery alone), addition of postop-
erative chemotherapy did not have any beneficial effect on 
survival and yielded no significant difference in the 5-year 
survival rate. Subsequently, another randomized controlled 
trial carried out in patients with esophageal squamous 
cell carcinoma using a different chemotherapy regimen 
(JCOG9204: comparison between surgery plus 2 courses of 
postoperative cisplatin + 5-FU and surgery alone) showed 
no clear intergroup difference in the overall survival rate. 
However, the disease-free survival time was significantly 
longer in patients given postoperative chemotherapy than 
in those treated by surgery alone. Thus, postoperative 
chemotherapy appeared to have a recurrence-preventive 
effect, particularly in patients with lymph node metasta-
sis. By contrast, no such beneficial effect of postoperative 
adjuvant therapy was noted in patients without lymph node 
metastasis.
A randomized controlled trial carried out in France com-
paring surgery with and without 6–8 courses of postopera-
tive cisplatin + 5-FU included patients undergoing palliative 
resection who accounted for about half of all the subjects. 
There was no significant difference in the median survival 
time between the two groups, and the researchers concluded 
that postoperative adjuvant chemotherapy with cisplatin and 
5-FU exerted no beneficial effect. A meta-analysis of these 
randomized controlled trials also showed no beneficial effect 
of adjuvant chemotherapy on the survival rate.
The results of surgery with and even without adjuvant 
therapy obtained from all previous JCOG clinical studies 
were much better than the results of surgery plus postop-
erative adjuvant therapy reported by clinical studies con-
ducted in Europe and North America. This may reflect the 
differences in the policy and accuracy of lymph node dis-
section between Japan and Western countries. This should 
be borne in mind when comparing the results of clinical 
studies carried out in Japan and those conducted in Europe 
and North America.
Thus, there is not enough evidence to show that adjuvant 
chemotherapy improves the overall survival rate of patients 
undergoing curative resection. However, a Japanese rand-
omized controlled study (JCOG9204) demonstrated a signif-
icant increase in the disease-free survival rate after adjuvant 
chemotherapy, showing the recurrence-preventive effect of 
this therapy, particularly in patients with lymph node metas-
tasis. Considering the fact that the accuracy of lymph node 
dissection is characteristically high in Japan and placing 
weight on the evidence obtained from this country, adjuvant 
chemotherapy (cisplatin + 5-FU, 2 courses) seems to have a 
role in the prevention of postoperative recurrence in patients 
with lymph node metastasis in whom curative resection has 
been achieved without any preoperative therapy.
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Adjuvant radiotherapy
Preoperative irradiation has long been considered a standard 
treatment in Japan. However, since there is no report defini-
tively documenting that preoperative irradiation improves the 
survival rate, the Esophageal Oncology Group of the JCOG 
performed a randomized controlled trial from 1981 to 1984 
to compare the outcomes of preoperative (30 Gy/15 frac-
tions) plus postoperative (24 Gy/12 fractions) irradiation with 
postoperative irradiation alone (50 Gy/25 fractions). Since a 
number of cases were excluded from the analysis in this study 
because of non-curative resection or surgical complications, 
the results may be somewhat unreliable. However, when the 
analysis was confined to the eligible patients who received 
treatment as per protocol, the overall survival rate was signifi-
cantly higher in the group administered postoperative irradia-
tion alone. Based on this finding, prophylactic postoperative 
irradiation came to be used commonly in Japan.
By contrast, 4 overseas randomized controlled trials com-
paring surgery with and without postoperative irradiation 
(usual fractionation, 45–60 Gy) demonstrated no significant 
increase in the survival rate, although the rate of local recur-
rence in the irradiated areas decreased in the group given 
postoperative irradiation. A meta-analysis based on these 
controlled studies also showed no increase in the survival 
rate in the group treated by postoperative irradiation. There-
fore, there is little evidence for recommending postoperative 
radiotherapy following curative resection as a standard treat-
ment. However, a subset analysis in a large-scale randomized 
controlled trial performed in China showed that postopera-
tive radiotherapy led to a significant increase in the survival 
rate in Stage III patients alone. Therefore, postoperative radi-
otherapy may be of clinical value for selected patients.
Chemotherapy
Summary
Chemotherapy in the treatment of esophageal carcinoma 
is usually combined with surgery or radiotherapy in the 
form of preoperative or postoperative adjuvant chemother-
apy or chemoradiotherapy. The use of chemotherapy not 
combined with other modalities is limited to patients with 
distant metastasis (M1b) or postoperative distant recur-
rence. Currently, 5-FU + cisplatin is the most commonly 
used combination regimen for chemotherapy. However, 
since there is no definitive evidence of prolongation of 
the survival time, this therapy is regarded as a palliative 
treatment.
Proven effective monotherapy drugs
Many chemotherapeutic drugs, such as 5-FU, cisplatin, 
mitomycin C, bleomycin, vindesine, adriamycin, pacli-
taxel, docetaxel, vinorelbine, nedaplatin, irinotecan, 
and gemcitabine are known to be effective in the treat-
ment of esophageal carcinoma (Table 3). However, while 
15–44 % of patients have been estimated to respond to 
monotherapy, cases of complete response (CR) are rare 
and no monotherapy has been shown to have a survival-
prolonging effect. At present, the most commonly used 
drugs are 5-FU and cisplatin. Basic studies have dem-
onstrated that these two drugs are effective when used 
as monotherapy, and exert a synergistic effect when 
combined and a sensitizing effect when combined with 
radiotherapy. In clinical, many reports were published 
about good results of these drags combination therapy. 
These are the reasons for the wide use of these two 
drugs. At present (as of February 2012), the use of pacli-
taxel is not yet covered by the national health insurance 
in Japan, although public knowledge-based application 
of this drug has been approved. The use of vinorelbine, 
irinotecan, and gemcitabine for the treatment of esopha-
geal carcinoma is also not covered by the national health 
insurance in Japan.
Efficacy in combination therapy
Although various combination therapies using cispl-
atin have been employed since this drug was introduced 
clinically (Table 4), the currently most commonly used 
Table 3  Efficacy of major 
monochemotherapeutic agents 
against carcinoma of the 
esophagus (drugs covered by 
the national health insurance in 
Japan)
a
 This drug is approved through 
public knowledge-based 
application (as of February 
2012)
Drug Dose and schedule No. of cases Response rate (%)
5-FU 500 mg/m2/day × 5 days 26 15
Mitomycin C 20 mg/m2 every 4–6 weeks 24 42
Cisplatin 50 mg/m2 every 3 weeks 24 25
Vindesine 3–4.5 mg/m2 every week 23 18
Docetaxel 70 mg/m2 every 3 weeks 48 21
Nedaplatin 100 mg/m2 every 4 weeks 29 52
Paclitaxela 100 mg/m2 every week × 6, 2-week withdrawal 52 44
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combination regimen is 5-FU + cisplatin. In other coun-
tries, this combination therapy is usually administered 
as follows: continuous intravenous infusion of 5-FU at 
1,000 mg/m2/day for 4–5 days, plus intravenous cisplatin 
at 100 mg/m2 on day 1. In contrast, a phase II clinical 
trial of 5-day continuous intravenous infusion of 5-FU 
at 700 mg/m2/day plus intravenous cisplatin at 70 mg/m2 
on day 1 carried out in Japan showed a response rate of 
36 %. A comparison between this combination therapy 
and best supportive care carried out overseas demon-
strated no definite prolongation of survival in the former 
group. However, this study included many patients in 
whom this therapy was used mainly as adjuvant chemo-
therapy. However, it excluded those in whom the meta-
static focus in the liver accounted for more than 30 % 
of the hepatic parenchyma and those who had peritoneal 
dissemination. Therefore, the effect of this combina-
tion therapy on survival remains unclear. Although in 
recent years, regimens containing paclitaxel, irinotecan, 
or gemcitabine have been tried overseas, and regimens 
using nedaplatin or docetaxel have been tried in Japan, 
no large-scale phase III trials of these regimens have 
been carried out. Thus, the merits of these regimens over 
the standard combination of 5-FU + cisplatin have yet 
to be demonstrated. Currently in Japan, the combination 
of 5-FU + cisplatin is commonly used as the first-line 
treatment, followed by docetaxel as a second-line treat-
ment. In any event, the effect of the use of chemotherapy 
alone, regardless of whether it is combination therapy 
or monotherapy, is limited, and chemotherapy not com-
bined with other treatment modalities is applied only to 
patients with unresectable metastatic lesions.
Cisplatin, a chemotherapeutic drug that is in wide 
use, is classified as a highly pro-emetic drug. Guidelines 
for appropriate use of antiemetic drugs recommend the 
triple-drug combination of a 5-HT3 receptor antagonist, 
corticosteroid, and aprepitant to prevent emesis while 
using cisplatin. For other drugs, it is necessary to check 
the risk of emesis against guidelines for appropriate use 




As compared to radiation monotherapy, concurrent chem-
oradiotherapy significantly increases the survival rate, 
although radiotherapy administered sequentially after 
induction chemotherapy does not. Concurrent chemora-
diotherapy is indicated for patients with T1-4N0-3M0 car-
cinoma (UICC-TNM classification, 2009 edition) in good 
general condition and for those with locally advanced car-
cinoma up to metastasis to the supraclavicular lymph nodes 
(M1). However, the risk of serious complications such as 
fistula formation is high in cases of unresectable locally 
advanced carcinoma (T4).
Because prolongation of the duration of irradia-
tion decreases the local control rate of radiation mono-
therapy, it is important to complete irradiation using a 
definitive dose (66–68.4 Gy) within 7 weeks. In defini-
tive concurrent chemoradiotherapy, the use of at least 
50 Gy/25 fractions/5 weeks with a conventional frac-
tionation protocol is necessary. The standard radiation 
dose for concurrent chemoradiotherapy in the USA is 
50.4 Gy/28 fractions. In contrast, in Japan, the stand-
ard radiation dose is 60 Gy/30 fractions/6–8 weeks for 
concurrent chemoradiotherapy, and its safety has already 
been demonstrated.
A randomized controlled trial carried out in Japan 
revealed that concomitant use of external beam radiation 
and intracavitary radiation is effective for patients with 
T1–2 esophageal carcinoma, a relatively early stage of 
the disease. However, recently chemoradiotherapy is used 
commonly, and the available evidence is not sufficient 
to recommend the addition of intracavitary radiation to 
chemoradiotherapy.
Previously, radiotherapy was primarily used for patients 
who were not suitable candidates for surgery or endoscopic 
mucosal resection (EMR). However, in recent years, radio-
therapy (in particular, chemoradiotherapy) has been widely 
used for both superficial carcinoma and locally advanced 
carcinoma, as definitive treatment.
Table 4  Efficacies of major combination therapies
a
 This regimen is approved through public knowledge-based application (as of February 2012)
b
 This regimen is not approved for insurance coverage (as of February 2012)
Drug Histologic type No. of cases Response rate (%)
5-FU + cisplatin Squamous cell carcinoma 39 36
Cisplatin + paclitaxela Squamous cell carcinoma/adenocarcinoma 32 44
Cisplatin + irinotecanb Squamous cell carcinoma/adenocarcinoma 35 57
Cisplatin + gemcitabineb Squamous cell carcinoma/adenocarcinoma 32 45
5-FU + nedaplatin Squamous cell carcinoma 38 40
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The standard radiotherapy used for esophageal carci-
noma is in accordance with the Radiotherapy Planning 
Guidelines 2008 (ed. by Japanese College of Radiol-
ogy, The Japanese Society for Therapeutic Radiology and 




A definitive radiotherapy protocol is used when control 
of all gross lesions leading to cure is expected. Definitive 
irradiation is the most suitable for cases with T1-4N0-3M0 
carcinoma (UICC-TNM classification, 2009 edition) and 
cases with locally advanced disease up to metastasis to the 
supraclavicular nodes (M1). In patients with a favorable 
general condition allowing combined use of chemotherapy, 
the standard treatment is chemoradiotherapy rather than 
radiation monotherapy.
Definitive chemoradiotherapy has been used for the 
treatment of postoperative recurrence in the regional lymph 
nodes in patients without distant metastasis or postopera-
tive residual tumor, as well as for definitive irradiation in 
fresh cases. It has been shown to provide favorable thera-
peutic results.
Target volume
Gross tumor volume (GTV) GTV includes the esopha-
geal primary foci (GTV primary) and metastatic lymph 
nodes (GTV nodal) as determined by endoscopy and CT. In 
cases of esophageal carcinoma, it is difficult to determine 
the presence of lymph node metastasis on the basis of the 
sizes of the lymph nodes. However, it has been reported to 
be relatively safe to treat lymph nodes measuring 5 mm or 
more in the minor axis as determined by CT or MRI, regard-
ing them as metastatic foci, to decrease the percentage of 
false-negative cases.
18F-fluorodeoxyglucose (FDG)-PET is useful for staging 
because it allows the detection of hidden distant metastases. 
However, the sensitivity and specificity of this technique to 
detect metastatic lymph nodes are not always high in cases 
of esophageal carcinoma; therefore, it may not be reason-
able to attempt to identify metastatic lymph nodes on the 
basis of PET findings alone for treatment planning. On the 
positive side, it has been reported that PET/CT can confirm 
the extent of the primary focus (GTV primary) better than 
those based on CT alone, if the threshold of FDG activity is 
set properly.
Clinical target volume 1 (CTV1) CTV1 is defined as the 
entire circumference of the esophagus including the GTV 
primary on endoscopy or CT, as well as possible micro-
scopic lesions within 3–4 cm cephalocaudally and regional 
lymph nodes. A study of resected specimens of esophageal 
squamous cell carcinoma in 34 patients showed that the 
mean extent of microscopic invasion from the GTV pri-
mary was 10.5 ± 13.5 mm. It has been reported that a CTV 
margin of 3 cm would cover the aforementioned extent of 
microscopic progression in 94 % of patients.
However, because EP and LPM lesions in cases of T1a 
carcinoma rarely metastasize to the lymph nodes, irradia-
tion of regional lymph nodes is not required. By contrast, 
lymph node metastasis is present in 10–50 % of cases of 
MM or SM superficial carcinomas. Therefore, prophylactic 
irradiation of the regional lymph nodes is required for these 
cases, as for cases of advanced esophageal carcinoma. 
Table 5 lists the standard CTV1 in relation to the site of the 
primary lesion. Currently, there is not enough evidence and 
there is no evidence-based consensus on which lymph node 
regions the CTV should extend to. The irradiation dose to 
these areas should be 40–46 Gy/20–23 fractions. In regard 
to chemoradiotherapy for superficial esophageal carcinoma 
(cT1N0M0), it has been reported that favorable therapeutic 
results can be obtained by localized irradiation, allowing 
a 3-cm margin inferiorly and superiorly, and a 1- to 2-cm 
margin anteriorly, posteriorly, and on both sides of the pri-
mary focus (GTV primary). Thus, extensive irradiation of 
regional lymph nodes may not be necessary for superficial 
esophageal carcinoma.
Clinical target volume 2 (CTV2) CTV2 after irradiation of 
40–46 Gy to CTV1 should cover the whole circumference 
of the esophagus including the GTV primary with addition 
of a margin of about 2 cm in the cephalocaudal direction 
and 0–0.5 cm in the lateral direction, and the area of meta-
static lymph nodes (GTV nodal) with an additional margin 
of about 0–0.5 cm in the lateral direction.
Planning target volume 1 (PTV1) The planning target vol-
ume at the beginning of radiotherapy (PTV1) should include 
CTV1 with an adequate margin (0.5–1.0 cm in the lateral 
direction and 1–2 cm in the cephalocaudal direction), allow-
ing for respiratory movements and errors in reproducing 
the patient’s fixation. Because respiratory movements are 
particularly large in the case of lower thoracic esophageal 
carcinoma, a margin of 0.8 cm in the lateral direction and 
1.8 cm in the cephalocaudal direction has been reported to 
be necessary.
Planning target volume 2 (PTV2) The planning target 
volume for the reduced exposure field at 40–46 Gy (PTV2) 
should include CTV2 with an adequate margin (0.5–1.0 cm 
in the lateral direction and 1–2 cm in the cephalocaudal 
direction).
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Radiotherapy planning and the irradiation method
Three-dimensional treatment planning based on CT images 
is recommended. This method allows an understanding of 
the 3-dimensional positional relationship between the tar-
get volume and the organs at risk, and is useful for imple-
menting high-accuracy radiotherapy to minimize exposure 
of the organs at risk. If a lesion cannot be visualized by 
CT, as in the case of superficial carcinoma, clipping to 
the upper and lower parts of the lesion under endoscopic 
guidance is required prior to CT imaging. Organs at risk 
that require particular attention in treatment planning for 
esophageal carcinoma include the lung, heart, and spinal 
cord.
The use of 6–10 MV X-rays is recommended for exter-
nal irradiation. An appropriate point in the PTV is chosen 
as the dose assessment point. Irradiation should be applied 
while restricting the cumulative maximum dose to the spi-
nal cord to 44–46 Gy or less by using the fixed multiple 
field technique or by changing the radiation field mid-
course. Intensity-modulated radiotherapy (IMRT) may be 
used for the treatment of cervical esophageal carcinoma at 
facilities that have radiation oncologists and medical physi-
cists who are familiar with treatment planning to secure 
adequate quality control of radiotherapy.
Dose fractionation
In general, the conventional fractionation method is used. 
The standard radiation dose for chemoradiotherapy used 
overseas is about 50 Gy/25–28 fractions/5–6 weeks. In 
contrast, in Japan, the standard radiation dose is about 
60 Gy/30 fractions/6–8 weeks for chemoradiotherapy, 
and 60–70 Gy/30–35 fractions/6–7 weeks for radiation 
monotherapy. Chemoradiotherapy is described in detail in 
chapter XI.
The overall treatment time is an important factor in 
radiotherapy for esophageal squamous cell carcinoma. The 
local control rate is known to decrease with increase in the 
overall treatment time of radiotherapy; therefore, in cases 
of radiation monotherapy, it is important to avoid prolonga-
tion of the overall treatment time as much as possible.
Intracavitary radiation
In Japan, superficial esophageal carcinoma is considered 
to be a suitable indication for intracavitary irradiation, 
because this technique of irradiation can deliver sufficient 
radiation dose to the superficial lesions. A retrospective 
analysis from a single institution indicated that a radiation 
boost by intracavitary irradiation for a superficial lesion of 
the esophagus yielded favorable therapeutic results. How-
ever, the report by Nemoto et al., who reviewed multicenter 
studies carried out in Japan, indicated that there was no 
difference in the survival rate between external radiation 
monotherapy and external radiotherapy combined with 
intracavitary irradiation in patients with superficial carci-
noma of the esophagus. While randomized controlled trials 
focusing on superficial esophageal carcinoma have never 
been done, randomized controlled trials of intracavitary 
irradiation for esophageal carcinoma, including advanced 
cases in Japan, reported that intracavitary irradiation was 
effective for esophageal carcinomas measuring 5 cm or less 
in the major axis or those with a depth of invasion corre-
sponding to T1 or T2. However, more recently, chemora-
diotherapy has come to be used commonly, and the efficacy 
and safety of an additional intracavitary radiation boost to 
chemoradiotherapy are not necessarily clear.
Table 5  Standard lymph node regions in relation to the site of the primary focus (CTV1)
Locations of regional lymph nodes of the esophagus on CT images are shown in the 10th edition of the Japanese Classification of Esophageal 
Cancer
Perigastric lymph nodes: Cardiac lymph nodes [1,2], lymph nodes along the lesser curvature [3], and lymph nodes along the left gastric artery 
[7]
There is no consistent consensus on CTV1 in cases of primary carcinoma originating in the middle thoracic esophagus (Mt)
Cervical esophagus (Ce) From the midsdle deep cervical lymph nodes [102-mid] to the lymph nodes at the tracheal 
bifurcation [107]
Upper thoracic esophagus (Ut) From the supraclavicular lymph nodes [104] to the middle thoracic paraesophageal lymph 
nodes [108]
Middle thoracic esophagus (Mt) a. From the supraclavicular lymph nodes [104] to the lower thoracic paraesophageal [110] 
or perigastric lymph nodes
b. From the lymph nodes along the recurrent laryngeal nerve [106-rec] and upper thoracic 
paraesophageal lymph nodes [105] to the lower thoracic paraesophageal [110] or per-
igastric lymph nodes
Lower thoracic esophagus (Lt) From the lymph nodes along the recurrent laryngeal nerve [106-rec] and upper thoracic 
paraesophageal lymph nodes [105] to the perigastric lymph nodes
Patients of advanced age or with complications Only lymph node regions around the primary focus
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For intracavitary irradiation, a balloon applicator meas-
uring 15–20 mm in diameter should be used to avoid une-
ven distribution of the radiation source. The point of dose 
assessment should be 5 mm lateral to the applicator surface 
(5 mm submucosal), and the dose on the mucosal surface 
should also be reported. Although there is no definite con-
sensus about the optimal dose and fractionation of intra-
cavitary irradiation because they are closely related to the 
combined external irradiation dose, the general practice is 
external irradiation at 50–60 Gy followed by intracavitary 
irradiation at 8–12 Gy/2–4 fractions (3–4 Gy per session). 
Because an increase in the fractional dose of intracavitary 
radiation is associated with an increased risk of late com-
plications, such as esophageal ulcers and perforation, 1–2 
sessions per week at a dose of 4 Gy or less per session for 
high-dose-rate irradiation, or at a dose of 6 Gy or less per 
session for low-dose-rate irradiation is recommended.
Complications
Major early adverse events include radiation dermatitis, 
radiation esophagitis, and radiation pneumonia. Radiation 
esophagitis is almost inevitable; however, the possibility 
of development of esophagomycosis or reflux esophagitis 
should also be borne in mind. Radiation pneumonia, which 
is sometimes a serious issue, requires differentiation from 
infectious pneumonia and carcinomatous lymphangitis.
As late adverse events, esophageal perforation and 
bleeding occur in some patients treated by radiotherapy. 
The incidence rate of late adverse events is relatively 
increased in cases of T4 disease. In cases where high-dose 
intracavitary irradiation is employed, special caution con-
cerning the occurrence of esophageal ulcers and perfora-
tion is necessary. The incidence of these conditions has 
been reported to be increased in patients given intracavi-
tary irradiation after chemoradiotherapy. Esophageal ste-
nosis may occur in patients with circumferential disease or 
those subjected to repeated EMR. Because radiation pneu-
monia may be fatal in patients of advanced age, it is neces-
sary to reduce the exposure dose to the lung in treatment 
planning. The possibility of thoracic vertebral compression 
fracture within the radiation field requires particular atten-
tion and should be differentiated from bone metastasis.
Pericardial effusion and constrictive pericarditis associ-
ated with radiation epicarditis and pleural effusion caused 
by radiation pleuritis have been reported to occur at high 
frequencies after chemoradiotherapy. Radiation myeli-
tis is a serious and rare late complication. There are case 
reports of radiation myelitis developing even in cases with 
an exposure dose to the spinal cord of only 44 Gy, suggest-
ing the need for particular vigilance regarding this com-
plication. In addition, irradiation of the cervical area may 
cause hypothyroidism a few years post-irradiation. Because 
hypothyroidism may serve as a risk factor for radiation epi-
carditis and radiation pleuritis, regular monitoring of the 
thyroid functions is necessary in long-surviving patients.
Radiotherapy for symptomatic relief
This type of radiotherapy is aimed at improving the subjec-
tive symptoms and QOL and not at obtaining an anticancer 
effect. Radiotherapy may be used for the primary focus to 
improve dysphagia in patients with esophageal carcinoma, 
or for the treatment of distant metastases such as bone 
metastasis and brain metastasis. Although intracavitary 
irradiation monotherapy has been suggested to be useful 
for improving dysphagia, this radiotherapeutic technique is 
seldom used for the management of dysphagia associated 
with esophageal carcinoma in Japan.
For palliative irradiation, it is important to set the mini-
mum necessary radiation field and total dose to achieve the 
treatment objective. The treatment should be completed 
within as short a period of time as possible, considering the 
general condition of the patient.
Chemoradiotherapy
Summary
Randomized controlled studies have demonstrated that 
chemoradiotherapy yields a significantly higher survival 
rate than radiation monotherapy in patients with esopha-
geal carcinoma; therefore, this therapeutic modality is 
regarded as the standard therapy for patients with esopha-
geal carcinoma when non-surgical treatment is the choice. 
Patients who can be the target of definitive chemoradiother-
apy include T1-3N0-3M0 cases (UICC-TNM classification, 
2009 edition), unresectable T4N0-3M0 cases, and cases 
with locally advanced disease up to metastasis to the supra-
clavicular nodes (M1). Some reports showed no signifi-
cant difference in the overall survival and recurrence-free 
survival between patients with resectable lesions treated 
by chemoradiotherapy or by surgery alone. However, in 
Japan, neoadjuvant chemotherapy followed by surgery is 
considered to be superior to chemoradiotherapy in patients 
with Stage IB–III disease (UICC-TMN classification, 
2009 edition), while the equivalence of chemoradiotherapy 
and surgery is considered in patients with Stage IA dis-
ease (T1N0M0, UICC-TNM classification, 2009 edition). 
Although the drug doses, radiation doses, and treatment 
schedules vary among different clinical studies, the most 
common protocol employed is combined chemotherapy 
with 5-FU plus cisplatin and concurrent radiotherapy at a 
total dose of 50-60 Gy. It is necessary to recognize that any 
of the reported treatment results can be reproducible only 
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when the chemotherapy and radiotherapy defined in the 
study are adequately applied.
Radiation dose in definitive chemoradiotherapy
In a randomized controlled trial of radiation monotherapy 
(64 Gy) and concurrent chemoradiotherapy (5-FU + cispl-
atin + radiation 50 Gy) for T1-4N0-1M0 esophageal car-
cinoma (corresponding to UICC-TNM classification, 2002 
edition) carried out by the US Radiation Therapy Oncology 
Group (RTOG), the 5-year survival rate was 0 % for the 
former and 26 % for the latter; the latter treatment yielded 
significantly better results (p < 0.0001). Thus, chemoradio-
therapy is strongly recommended in non-surgical treatment. 
In regard of the timing of chemotherapy and radiotherapy, 
a meta-analysis showed that concurrent chemoradiother-
apy is associated with a significantly lower mortality rate 
(p < 0.0001) than sequential chemoradiotherapy. In addi-
tion, a randomized controlled study (RTOG9405/INT0123) 
carried out succeedingly to RTOG 85-01 that compared 
chemoradiotherapy using standard-dose (50.4 Gy) and 
high-dose (64.8 Gy) radiation in patients with T1-4N0-1M0 
esophageal carcinoma (corresponding to UICC-TNM clas-
sification, 2002 edition) revealed no superiority of high-
dose radiation over standard-dose radiation in terms of 
the median survival time, the 2-year survival rate, and the 
local control rate, and concluded that the standard radia-
tion dose for chemoradiotherapy using a combination of 
5-FU plus cisplatin should be 50.4 Gy (1.8 Gy × 28 times). 
By contrast, a radiation dose of 60 Gy has been used pre-
dominantly in studies carried out in Japan. Although the 
standard radiation dose has not yet been established in 
Japan, change to 1.8 Gy/fraction × 28 times (total dose of 
50.4 Gy) is now under review at some facilities. For infor-
mation on the method of irradiation and dose fractionation, 
see “Radiotherapy”.
Chemotherapy used in definitive chemoradiotherapy
The standard chemotherapy regimen is 5-FU + cisplatin. 
In the aforementioned RTOG9405/INT0123 study, a course 
of 4 days’ continuous intravenous infusion of 5-FU at 
1,000 mg/m2/day plus intravenous cisplatin at 75 mg/m2 on 
day 1 was repeated every 4 weeks up to a total of 4 courses 
(concurrent radiation was used in the initial 2 courses). 
In Japan, although use of the 5-FU + cisplatin regimen is 
variable, a phase II clinical study (JCOG9708) of chemo-
radiotherapy (5-FU + cisplatin + irradiation of 60 Gy) for 
cases of Stage I esophageal carcinoma (T1N0M0, UICC-
TNM classification, 1997 edition [*corresponding to Stage 
IA: T1N0M0 in the 2009 edition]) conducted by the JCOG 
used 2 courses of 4 days’ continuous intravenous drip 
infusion of 5-FU at 700 mg/m2/day plus intravenous drip 
infusion of cisplatin at 70 mg/m2 on day 1 repeated every 
4 weeks. In the JCOG9708 study, the complete response 
rate was 87.5 %, the 4-year survival rate was 80.5 %, and 
the 4-year progression-free survival rate was 68 %, suggest-
ing results equivalent to those of surgery. Currently, a phase 
III clinical study (JCG0502) comparing chemoradiother-
apy with surgery is underway. In another phase II JCOG 
study (JCOG9906) of chemoradiotherapy (5-FU + cispl-
atin + irradiation of 60 Gy) performed in cases of resect-
able Stage II–III esophageal carcinoma, a course of 5 days’ 
continuous intravenous infusion of 5-FU at 400 mg/m2/day 
for 2 weeks plus intravenous cisplatin at 40 mg/m2 on days 
1 and 8 was repeated every 5 weeks for a total of 4 courses 
(the initial 2 courses were combined with concurrent irradi-
ation). However, the use of chemotherapy according to the 
RTOG regimen is now under consideration in Japan. In any 
case, 2 courses of concurrent chemoradiotherapy are com-
monly administered. Although the use of additional chemo-
therapy after chemoradiotherapy is variable; 2 courses of 
additional chemotherapy are often administered for Stage 
II–III lesions. Table 6 shows the main schedules used in 
definitive chemoradiotherapy.
Adverse events associated with definitive 
chemoradiotherapy
Adverse events associated with chemoradiotherapy may be 
attributable to chemotherapy, radiotherapy, or both, and it 
is difficult to strictly distinguish among these causes. Major 
early adverse events include nausea, vomiting, myelosup-
pression, esophagitis, stomatitis, diarrhea, constipation, and 
radiation pneumonitis. In particular, radiation pneumonitis 
may be fatal, and it is desirable to identify factors that may 
predict the development of this condition. In this regard, it 
has been suggested that dose–volume histogram (DVH) 
parameters of irradiation may be useful. On the other hand, 
late adverse events include radiation pericarditis, radiation 
pleuritis, pleural effusion, and pericardial effusion. Hypo-
thyroidism may occur in patients who have received radia-
tion in the cervical area, which may also be accompanied by 
pleural effusion or pericardial effusion, necessitating caution. 
Although rare, the occurrence of thoracic vertebral compres-
sion fracture or radiation myelitis has also been reported 
(see “Radiotherapy”). In regard of the late toxic effects, it 
is considered that the radiation dose to organs at risk such 
as the lung and heart should be carefully considered. Use of 
a 3-dimensional radiation planning technique based on CT 
images aimed at reducing the toxic effects is now common.
Among other possible adverse events during chemo-
radiotherapy for esophageal carcinoma, special attention 
should be paid to the syndrome of inappropriate secretion 
of antidiuretic hormone (SIADH) attributable to cispl-
atin and leukoencephalopathy attributable to 5-FU. Early 
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detection and prompt medication, particularly prompt dis-
continuation of medication if the patient is on some drug 
therapy, are necessary.
Follow-up after therapy
Contrast-enhanced CT and endoscopic examination are 
generally used for follow-up observation after definitive 
chemoradiotherapy. Although there is no definitive evi-
dence for the appropriate timing of the response evaluation 
and follow-up observation, patients are usually examined 
3–4 weeks after completion of chemoradiotherapy at the 
end of each course of additional chemotherapy, and sub-
sequently every 3 months during the first year, and every 
4–6 months thereafter. Residual carcinoma or recurrence 
after chemoradiotherapy is found most frequently in the 
primary tumor in the esophagus and in the lymph nodes, 
usually within 1–2 years after the start of therapy. There-
fore, if salvage therapy is considered, evaluation of the 
primary site is important. The initial endoscopic evalua-
tion of the primary site within 75–90 days after the start of 
chemoradiotherapy, followed by a second evaluation within 
1 month of the initial evaluation, is considered to be most 
effective in determining the presence/absence of exacerba-
tion and judging whether a CR has been achieved. Because 
patients with esophageal carcinoma are known to show a 
relatively high likelihood of developing multiple carcino-
mas, with carcinomas developing de novo in other parts 
of the esophagus or in other organs (head and neck region, 
stomach, large intestine), careful follow-up observation and 
appropriate diagnostic measures are required.
Salvage therapy for local remnant or recurrent lesions 
after definitive chemoradiotherapy
Salvage therapy using endoscopy or surgery has recently 
been tried for the treatment of local remnant or recurrent 
lesions after definitive chemoradiotherapy (see “Salvage 
surgery”). As for salvage endoscopic treatment, endo-
scopic mucosal resection (EMR), endoscopic submucosal 
dissection (ESD), and photodynamic therapy (PDT) have 
been tried, and favorable long-term results with accept-
able safety have been reported. However, the indications 
for these treatments and selection of the appropriate treat-
ment method have not yet been adequately evaluated. Sal-
vage surgery (see “Salvage surgery”) provides cure in some 
cases; however, the incidence of operation-related adverse 
events and operation-related mortality is high, and the opti-
mal surgical technique and extent of lymph node dissection 
have not yet been established. Therefore, salvage surgery 
is not employed in general practice. It has been reported 
that long-term survival may be achieved after salvage sur-
gery when the depth of invasion of the residual or recur-
rent lesion is shallow, or when there is no residual or recur-
rent lymph node metastasis. To facilitate early detection of 
remnant or recurrence of the primary focus after definitive 
chemoradiotherapy, strict follow-up by endoscopy is neces-
sary, bearing in mind the observations that the greater the 
T factor of the pretreatment staging, the more likely recur-
rence is, and that recurrence often occurs in the form of 
submucosal tumor-like elevation.
Diagnosis and treatment of Barrett’s esophagus 
and Barrett’s carcinoma
Summary
Esophagus showing Barrett’s mucosa is called Barrett’s 
esophagus. Barrett’s mucosa refers to the columnar epi-
thelial metaplasia that extends from the stomach to the 
esophagus in a continuous fashion and can be confirmed 
by endoscopy. Histological confirmation of specific colum-
nar epithelial metaplasia is not required. Histologically, 
Table 6  Main schedules used in definitive chemoradiotherapy
Schedules without radiation split are being adopted in several ongoing clinical trials in Japan
Author Target stage Chemotherapy drugs Radiation dose
5-FU Cisplatin Period × No.  
of courses
Single dose  
× No. of sessions
Split
RTOG T1-4N0, 1M0 1000 mg/m2/day × 4 days 75 mg/m2 every 4 weeks × 4 1.8 Gy × 28 None
JCOG9708 T1N0M0 700 mg/m2/day × 4 days 70 mg/m2 every 4 weeks × 2 2.0 Gy × 30 1 week
JCOG9906 T1N1M0 or T2-3N0-1M0 400 mg/m2/day × 10 days 40 mg/m2 × 2 every 4 weeks × 2 2.0 Gy × 30 2 week
Ohtsu T4/M1/LYM 400 mg/m2/day × 10 days 40 mg/m2 × 2 every 5 weeks × 2 2.0 Gy × 30 2 weeks
Nishimura T4M0 300 mg/m2/day × 14 days 10 mg/m2 every 4 week × 2 2.0 Gy × 30 1 week
JCOG0303 T4/M1LYM 700 mg/m2/day × 4 days 70 mg/m2 every 4 weeks × 2 2.0 Gy × 30 1 week
KROSG0101 Stage II–IVA 700 mg/m2/day × 5 days 70 mg/m2 every 4 weeks × 2 2.0 Gy × 30 1 week
Nakajima Stage II/III 1,000 mg/m2/day × 4 days 75 mg/m2 every 4 weeks × 4 1.8 Gy × 28 None
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Barrett’s mucosa exhibits one of the following features: 
(1) proper esophageal glands or ducts beneath the overly-
ing columnar epithelium; (2) squamous epithelial islets in 
the columnar epithelium; (3) double structure of the lam-
ina muscularis mucosae. Barrett’s carcinoma is defined as 
adenocarcinoma occurring in Barrett’s mucosa. The defi-
nitions of early, superficial, and advanced carcinomas are 
the same as those of esophageal carcinoma, regarding the 
deep-seated lamina muscularis mucosae as the original 
lamina muscularis mucosae. Treatment of Barrett’s carci-
noma is planned in accordance with the treatment of squa-
mous cell carcinoma of the esophagus at the same loca-
tion in the esophagus. Endoscopic resection is indicated 
for lesions confined to the lamina propria mucosae (EP, 
SMM, and LPM). Relative indications are currently under 
consideration.
Diagnosis and treatment of double carcinoma (head 
and neck, stomach)
Summary
Patients with esophageal carcinoma frequently develop 
carcinoma of other organs, particularly of the upper aerodi-
gestive tract, including head and neck carcinoma, gastric 
carcinoma, and lung carcinoma. Preoperative examination 
and postoperative follow-up must be carried out bearing 
in mind the possible presence of double/multiple lesions. 
Therapeutic strategies and problems involved in treatment 
vary widely according to the type, stage, and time of onset 
of the other lesions. It is important to select the surgical 
technique and the treatment method in a well-balanced 
manner, taking into consideration the general condition of 
the patient, and the prognosis of the esophageal lesions and 
second primary lesions.
Double carcinoma is defined as the co-existence of 
two primary carcinomas in different organs. Patients with 
esophageal lesion are reported to show a higher incidence 
of double carcinoma as compared to the incidence of malig-
nancy in the general population. This higher incidence of 
double carcinoma in esophageal carcinoma patients may be 
explained by the sharing of risk factors of carcinomas of 
the upper aerodigestive tract. We would also like to empha-
size the concept of field cancerization here.
The incidences and types of double carcinoma vary 
according to the year of survey, the duration of observation, 
and the specialization level of the facilities. According to 
the national registry of the Japan Esophageal Society, about 
20 % of patients with esophageal lesion have a second pri-
mary lesion, being synchronous in 8 % and metachronous 
in 12.2 % of the cases. The most frequent type of double 
carcinoma was gastric lesions, followed by head and neck 
lesions (pharyngeal carcinoma), colorectal lesions and lung 
lesions, in descending order of frequency.
In addition, according to the 2007 statistics of the Japa-
nese Association for Thoracic Surgery, the incidence of 
double carcinoma, including second primary carcinomas 
preceding esophageal carcinoma but excluding the ones 
following esophageal carcinoma, was 12.9 %, with the pro-
portion of synchronous double lesions at 7.45 %. The type 
of double lesions was most frequently gastric lesions, fol-
lowed by head and neck lesions.
From the viewpoint of diagnosis and treatment of esoph-
ageal lesions, the presence/absence of a second primary 
head and neck lesions is an important issue. A number of 
studies on double carcinoma in the esophagus and the head 
and neck region have so far been reported. Some reports 
claim that head and neck carcinomas may be the most fre-
quently occurring second carcinoma in association with 
esophageal carcinoma.
Among patients with esophageal lesions, most studies 
report a frequency of head and neck lesions of about 10 %, 
with pharyngeal lesions the most frequent type of head and 
neck lesions encountered in these cases. Some character-
istic features that may help in predicting the presence of 
head and neck lesions in patients with esophageal lesions 
include the presence of multiple esophageal lesions and the 
existence of multiple zones in the esophagus showing nega-
tive iodine staining.
In recent years, advances in endoscopic techniques, 
including magnifying endoscopy and image-enhanced 
endoscopy and increased attention to the head and neck 
region in patients with esophageal carcinoma, have 
increased the detection rate of head and neck carcinoma in 
the early stage by endoscopic examination of the upper gas-
trointestinal tract. Image-enhanced endoscopy has recently 
been introduced in the field of otorhinolaryngology, and the 
usefulness of this technique as compared to conventional 
white-light endoscopy has been reported.
Although esophageal carcinoma and gastric carcinoma 
share few risk factors, smoking is said to be a common 
risk factor for both esophageal carcinoma and gastric car-
cinoma. The high prevalence of atrophy of the gastric 
mucosa due to Helicobacter pylori infection and the high 
morbidity rate of gastric carcinoma due to environmental 
factors in Japan may exert a great influence to incidence of 
concomitant gastric lesion with esophageal cancer.
As a part of double/multiple carcinomas, carcinomas 
developing in the gastric tube after esophageal reconstruc-
tion pose another important problem.
When carrying out pretreatment examination of patients 
with esophageal carcinoma, due caution is necessary, 
because double carcinomas frequently involve areas that 
may greatly influence the choice of the particular therapeu-
tic strategies used.
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Follow‑up observation after treatment of esophageal 
carcinoma
The purposes of follow-up observation after treatment of 
esophageal carcinoma are (1) early detection and early 
treatment of recurrence and (2) early detection and early 
treatment of multiple esophageal carcinomas and double 
carcinomas involving other organs. In addition, follow-up 
observation is important from the point of view of general 
management of the patient after treatment and maintaining 
the patient’s QOL.
The methods used for follow-up observation after treat-
ment of esophageal carcinoma depend on the initial treatment 
employed and the stage of the disease at the time of the ini-
tial treatment. The patient follow-up is important for possible 
recurrence, bearing in mind the fact that early detection and 
early treatment of recurrence may allow prolongation of life. 
It is also important to exercise caution for the development of 
metachronous multiple esophageal carcinoma or metachro-
nous multiple carcinoma of other organs, such as gastric car-
cinoma or head and neck carcinoma. Formulation of an effec-
tive follow-up protocol based on general agreements by many 
doctors in Japan and verification of its efficacy are required.
Follow-up observation after endoscopic resection
Because the indications and types of additional treatment 
after endoscopic resection vary, and a substantial number 
of patients undergo follow-up observation alone, there 
is no standard method for follow-up observation. Local 
recurrence after endoscopic resection is often seen within 
1 year after the initial treatment, but may also occur after 
2–3 years. Therefore, long-term follow-up is necessary. 
Esophageal endoscopy with iodine staining is mainly used 
for the detection of local recurrence. Although some reports 
propose examinations at 6-month intervals, other reports 
recommend examinations at 3-month intervals during the 
first year after resection. Patients who undergo fractional 
resection or who have multiple zones of negative iodine 
staining require more detailed endoscopic examination of 
the esophagus. Lymph node recurrence and organ recur-
rence may be found after 2–3 years; therefore, periodic 
long-term observation is necessary.
Patients should be followed up at 6- to 12-month inter-
vals by cervical and abdominal ultrasonography, thoracoab-
dominal contrast CT, and/or EUS. Follow-up methods after 
endoscopic resection suggested by JCOG0508 study (phase 
II study on efficacy of combined treatment of endoscopic 
mucosal resection [EMR] and chemoradiotherapy for clini-
cal Stage I esophageal carcinoma [T1N0M0]) included 
clinical examination, cervical to abdominal contrast- 
enhanced CT, and measurement of the serum levels of the 
tumor marker SCC every 4 months until 3 years after EMR.
Follow-up observation after radical surgery
Recurrence after radical surgery has been reported to occur 
in 28–47 % of patients in Japan. A recurrence rate of 50 % 
or more is not rare in reports from Europe and North Amer-
ica. Among patients with recurrence, the timing of recur-
rence is within 1 year after surgery in 54–79 % of patients 
and within 2 years after surgery in 80–98 % of patients. 
Although rare, recurrence after more than 2 years can also 
occur, necessitating caution. The mode of recurrence may 
be lymph node metastasis, local recurrence, organ metas-
tasis, or disseminated recurrence; a combination of these is 
also encountered frequently.
Currently, the actual follow-up protocol employed after 
radical surgery for esophageal carcinoma is left to the discre-
tion of the treating facility. There are no reports of the benefit 
of regular follow-up observations or of effective methods of 
follow-up observation. Examination for recurrence basically 
consists of head and neck US, thoracoabdominal contrast-
enhanced CT, and bone scintigraphy. At many facilities, 
examination by US or CT is repeated every 3–6 months, 
often with some variations of the intervals according to 
the degree of progression and the number of years elapsed 
after surgery. Follow-up is generally carried out for 5 years, 
although some facilities continue to follow up their patients 
for 10 years. During the implementation of diagnostic imag-
ing, many facilities add examination by interview, physical 
examination, and measurement of tumor markers.
Follow-up observation after definitive chemoradiotherapy
Although CT and esophageal endoscopy are usually 
employed for follow-up observation after definitive 
chemoradiotherapy, there have been no reports providing 
evidence for establishing the optimal frequency for such 
examinations or the duration of follow-up. In most cases, 
these examinations are performed at 3–4 weeks after 
the end of chemoradiotherapy and after the end of each 
course of additional chemotherapy. Thereafter, follow-
up examinations are generally carried out every 3 months 
during the first year after therapy, and every 4–6 months 
from the second year onward after therapy. Residual car-
cinoma or recurrence after chemoradiotherapy is found 
frequently in the primary focus in the esophagus or in 
the regional lymph nodes, and in most cases recurrence 
occurs within 1–2 years after the start of therapy (see 
“Chemoradiotherapy”).
After definitive chemoradiotherapy for esophageal car-
cinoma, observation for possible late adverse events related 
to radiotherapy such as radiation pneumonitis, pleural effu-
sion, and pericardial effusion is necessary, in addition to 
examinations for recurrence. These aforementioned dis-
orders may cause deterioration of a patient’s QOL, and 
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radiotherapy-related late toxicity may even lead to death 
(see “Radiotherapy”).
Surveillance for metachronous multiple esophageal 
carcinomas and multiple carcinomas arising from other 
organs
Esophageal carcinoma is relatively frequently accompanied 
by metachronous multiple esophageal carcinoma. In addi-
tion, the occurrence of metachronous carcinomas in other 
organs, such as gastric carcinoma and cancer of the head 
and neck region, is not rare. Metachronous carcinoma of 
other organs has been reported as the predominant cause of 
postoperative death in pN0 patients. Bearing this in mind, 
it is necessary to perform endoscopic examination of the 
upper gastrointestinal tract and to observe the areas from 
the pharynx to the entire esophagus (remaining esophagus 
in resected cases) and the stomach regularly and carefully. 
Surveillance for the development of colorectal carcinoma 
or other carcinomas is also necessary.
Treatment of recurrent esophageal carcinoma
Summary
The initial treatment for esophageal carcinoma is selected 
from a wide variety of options, including endoscopic treat-
ment, radical surgery, and definitive chemoradiotherapy. 
Therefore, treatment of recurrent esophageal carcinoma 
should be determined according to the modality selected 
for the initial treatment. In addition, treatment of recur-
rent carcinoma varies according to the type of recurrence, 
i.e., lymph node metastasis, local recurrence, distant organ 
metastasis, or the combination of these. The general con-
dition of the patient at the time of recurrence also exerts 
influence on the selection of treatment. Recurrence is not 
rare even in patients in whom the initial treatment has been 
properly implemented. Large-scale clinical trials to clarify 
issues related to treatment of recurrence are difficult to con-
duct. Recurrent carcinoma may be curable depending on 
the type of recurrence, and aggressive treatment may be 
desirable. Treatment, however, is often aimed at suppres-
sion of tumor aggravation and improvement of the QOL.
Treatment of recurrence after endoscopic resection
Although local recurrence after endoscopic mucosal resec-
tion most often occurs within 1 year after the initial treat-
ment, it may even occur after 2–3 years in some cases. 
In recent years, the indications for endoscopic resection 
have been extended from the aspect of clinical research. 
The indications and types of additional treatment after 
endoscopic resection are variable, and quite a number of 
patients are followed up without any additional treatment.
Treatment of recurrence after radical surgery
Recurrence after radical surgery has been reported to occur 
in 28–47 % of patients in Japan. Reports of recurrence rates 
of 50 % or more are not rare from Europe and North Amer-
ica. In relation to the mode of recurrence, lymph node or 
local recurrence is found in 22–68 % of patients, and dis-
tant organ metastasis in 12–51 % of patients; the two types 
of recurrences have been reported to occur in combina-
tion in 7–27 % of patients. Lymph node recurrence usually 
involves the cervical or superior mediastinal lymph nodes, 
and distant organ recurrence most frequently involves the 
lung, followed by the liver, bone and brain, in descend-
ing order of frequency. Metastasis to the small intestine or 
colon has also been reported.
The survival rate of patients with recurrence after radical 
resection of esophageal carcinoma is extremely poor, with 
the median survival time from the diagnosis of recurrence 
reported to be 5–10 months. However, long-surviving cases 
and cases of complete cure do exist; therefore, aggressive 
treatment is desirable.
Treatment of recurrence after radical resection of esoph-
ageal carcinoma is selected on the basis of the site, type, 
and extent of recurrence. Treatment also depends on the 
general condition of the patient at the time of recurrence, 
whether the recurrence is within or outside the scope of 
surgical manipulation, and whether or not the patient has 
received radiation pre- or postoperatively. Therefore, there 
is little data on the treatment results from a large number of 
patients with various clinical conditions.
Treatment of recurrence in cases showing CR 
after definitive chemoradiotherapy
It has become more common in recent years to adopt 
definitive chemoradiotherapy as the initial treatment, 
not only for cases of unresectable esophageal carcinoma, 
but also for those with resectable esophageal carcinoma. 
Although this therapy yields a relatively high rate of CR, 




Although palliative care should be provided in all fields of 
cancer, a decrease in the patient’s QOL is particularly com-
mon in patients with esophageal carcinoma, caused by the 
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difficulty in swallowing, malnutrition, and/or cough due to 
fistula formation. Consideration of procedures for symp-
tom relief and maintenance and improvement of the QOL 
is required from the initial stages of treatment. However, 
selection of such procedures is currently left to the dis-
cretion of the treating institution. Close investigation of 
this issue would be desirable in the future. All health-care 
providers should acquire the basic knowledge and skills 
involved in the field of palliative medicine.
According to the WHO (2002), palliative care is defined 
as “an approach that improves the quality of life of patients 
and their families facing problems associated with life-
threatening illness, through the prevention and relief of 
suffering by early identification and impeccable assess-
ment and treatment of pain and other problems, physical, 
psychosocial and spiritual.” Palliative care should ideally 
begin when a patient is diagnosed as having cancer. This 
type of care is needed by all cancer patients and is provided 
in daily clinical practice. Palliative care requires a team 
approach that includes not only the doctors in charge and 
nurses, but also psycho-oncology specialists, pharmacists, 
social workers, and physical therapists. It has been pointed 
out that in particular, the role of a specialist nurse as a team 
leader is important in the palliative care of patients with 
esophageal carcinoma.
It is not rare, particularly in cases of esophageal carci-
noma, that the patient has decreased QOL from the time of 
diagnosis because of difficulty in swallowing and malnu-
trition due to esophageal stenosis, cough due to mis-swal-
lowing, or a fistula and chest pain due to the tumor. It is 
important to provide palliative care and treatment for the 
purpose of maintaining or improving QOL in parallel with 
the initial treatment that is aimed at cure of the disease.
Important issues in the palliative care of patients with 
end-stage esophageal carcinoma include difficulty in swal-
lowing due to esophageal stenosis and the resultant mal-
nutrition, the symptoms arising from airway stenosis and 
fistula formation to the airway, and cachexia and other 
symptoms due to distant metastasis and hypercalcemia. 
Among these, relief of symptoms arising from esopha-
geal stenosis, airway stenosis, or fistula formation may be 
attempted by palliative treatments such as radiotherapy, 
chemoradiotherapy, esophageal stent insertion, airway stent 
insertion, and esophageal bypass (see “Radiotherapy” and 
“Chemoradiotherapy”).
Gastrostomy or enterostomy as well as intravenous 
hyperalimentation may be performed to deal with malnu-
trition. These palliative treatments are typically employed 
for patients with esophageal carcinoma. Correct decisions 
as to the method and timing of implementation of these 
treatments are critical in the provision of palliative care for 
patients with end-stage esophageal carcinoma.
However, there have been few large-scale studies that 
have evaluated the efficacy and safety of various treat-
ments and procedures in palliative medicine for patients 
with esophageal carcinoma. There have been no studies on 
the possibility of radiotherapy or chemotherapy providing 
survival advantage over best supportive care. However, it 
is a fact that in the actual clinical setting, a certain propor-
tion of patients who have undergone these treatments have 
shown marked improvement in their QOL. Health-care pro-
viders should be skilled in palliative treatments and proce-
dures specific to esophageal carcinoma, and the appropriate 
treatments should be employed proactively after obtaining 
informed consent from the patients.
In addition, health-care providers who are engaged 
in the treatment of esophageal carcinoma often encoun-
ter fatal conditions, such as acute respiratory arrest due 
to airway obstruction or massive hematemesis due to 
perforation into the aorta. In many cases, rescue of the 
patient is difficult once these events occur. It is important 
to give adequate explanation in advance about the possi-
ble occurrence of such events, particularly to the patients’ 
families. Because the patients and their families have to 
live with the fear of sudden death or sudden change in 
clinical condition, provision of psychological support and 
mental care to both are indispensable. To treat carcinoma-
related pain, procedures described in the Clinical Guide-
line for Pharmacological Management of Cancer Pain 
issued by the Japanese Society for Palliative Medicine are 
recommended.
Therapeutic efficacy and guidelines in Europe 
and North America: including the results of prognostic 
studies based on national registries
Summary
Unlike the situation in Japan, in Europe and North Amer-
ica, adenocarcinomas originating in the lower esophagus 
account for a large proportion of esophageal lesions. There-
fore, the methods of treatment and their results are not nec-
essarily comparable to those in Japan.
A simple comparison of endoscopic treatments in Japan 
and Western countries is precluded by differences in the 
criteria for selection of suitable candidates. There are no 
well-established guidelines.
Transhiatal esophagectomy is common, reflecting the 
increase in the frequency of lower esophageal adeno-
carcinoma. The extent of lymph node dissection is often 
restricted to the middle and lower mediastinum. Although 
there are no large differences from Japan in terms of surgi-
cal indications in relation to the disease stage, the surgical 
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results have not been satisfactory in Europe and North 
America.
The reported efficacy of neoadjuvant chemotherapy var-
ies between Europe and North America. US Guidelines 
restrict neoadjuvant chemotherapy to carcinomas of the 
lower esophagus and the esophagogastric junction, and 
recommend neoadjuvant chemoradiotherapy for carcinoma 
arising in other parts of the esophagus. The England/Wales 
and Scotland, guidelines recommend 2 courses of neoadju-
vant chemotherapy for cases with resectable disease, but do 
not recommend neoadjuvant chemoradiotherapy.
In regard to non-surgical treatment, as chemoradiother-
apy has been shown to yield better results than radiation 
monotherapy; guidelines published in Europe and North 
America both recommend chemoradiotherapy as do those 
published in Japan.
There are differences in the epidemiology of esopha-
geal carcinoma between Japan and Europe/North America, 
which make it impractical to simply compare the methods 
and results of treatment between these regions. In regard 
to the histologic type, squamous cell carcinoma accounts 
for more than 90 % of all cases of esophageal carcinoma 
in Japan, whereas adenocarcinoma accounts for more than 
50 %, and squamous cell carcinoma for less than 40 % of 
cases in Europe and North America. As for the location of 
the tumor, tumors arising in the middle thoracic esophagus 
are reported as the most frequent, accounting for more than 
50 % of all cases in Japan, whereas lesions arising in the 
lower thoracic esophagus are reported to account for more 
than 50 % of the cases in Europe and North America. The 
past two decades have seen an increase in the frequency of 
adenocarcinoma in Western countries, and it is reported that 
Barrett’s esophagus developing from obesity and GERD 
have been reported as background factors for this increase. 
Therefore, these factors account for the differences in ther-
apeutic strategies and treatment results between Japan and 
the US/Europe.
Guidelines for the diagnosis and treatment of esopha-
geal carcinoma have also been published in some Western 
countries. These include 4 comprehensive guidelines, i.e., 2 
guidelines from the USA, 1 from the UK, and another from 
Scotland. In the USA, Physician Data Query (PDQ) from 
the National Cancer Institute (NCI) and information from 
the National Comprehensive Cancer Network (NCCN) are 
available on the Internet, and the information is updated 
continually, with data added from the latest literature. In 
particular, the NCCN guidelines provide an algorithm 
to facilitate selection of the appropriate treatment. The 
strength of recommendation is categorized according to the 
level of evidence. In the guidelines published in England/
Wales and Scotland, the levels of evidence are specified as 
in the Japanese guidelines. They provide specific informa-
tion on the epidemiology and pathogenesis, perioperative 
management, and postoperative complications as well as 
on the palliative treatment of esophageal carcinoma.
Endoscopic treatment
Although there are reviews on endoscopic treatment from 
Europe and North America, they differ from reports pub-
lished in Japan in those cases of high-grade dysplasia are 
included as target lesions, and photodynamic therapy 
(PDT) is also included as a type of treatment. Therefore, 
a simple comparison with reports from Japan is not possi-
ble. The reported 5-year survival rate after EMR is 87.7 % 
in Japan, according to the national statistics published in 
2002.
It is rare in Western countries for esophageal carci-
noma to be detected at an early stage; therefore, EMR is 
not commonly performed. Therefore, guidelines regard-
ing endoscopic treatment are limited. Although the NCCN 
guidelines recommend EMR for mucosal carcinoma (Tis or 
T1a), the NCI guidelines recommend surgery for Stage 0 
lesions. In the Scottish guidelines, EMR is recommended 
for carcinomas confined to the mucosal layer. The Eng-
land/Wales guidelines contain no description of endoscopic 
resection.
Surgery
In the USA, transhiatal esophagectomy without thoracot-
omy is regarded as the standard surgical treatment tech-
nique for esophageal carcinoma for the following reasons: 
the results of resection are poor due to the prevalence of 
advanced carcinoma; surgical complications are frequent 
because of the high rate of high risk patients; carcinoma in 
the lower esophagus is frequent; no difference in the recur-
rence-free survival has been reported between transhiatal 
esophagectomy and subtotal esophagectomy via right 
thoracotomy accompanied by lymph node dissection and 
complications are less frequent with the former procedure. 
The extent of lymph node dissection is often restricted to 
the middle and lower mediastinum, and dissection covering 
all the three regions (cervical, thoracic, and abdominal) is 
not generally performed. Table 7 shows the results of rand-
omized controlled trials of surgical treatment of esophageal 
carcinoma reported in and after 1990, and the 2002 Japa-
nese national registry data. Although there are variations in 
the stages considered for resection among overseas studies, 
the reported 5-year survival rate is generally about 25 % or 
less, being significantly different from the corresponding 
rate of 44.1 % in all cases treated by resection in Japan.
According to the NCCN guidelines, surgery is indi-
cated for Stage 0-III or resectable Stage IVA carcinoma 
of the esophagus. As for cases of cervical esophageal 
carcinoma, the NCCN guidelines state that definitive 
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chemoradiotherapy should be administered for carcinomas 
in this region and those located less than 5 cm from the cri-
copharynx, with no consideration of surgery.
Preoperative and postoperative adjuvant therapy
Preoperative adjuvant therapy A meta-analysis of several 
randomized controlled trials performed in Europe and North 
America to examine the usefulness of neoadjuvant chemother-
apy revealed no consistent benefit of neoadjuvant chemotherapy 
on survival. Thus, the efficacy of neoadjuvant chemotherapy for 
patients with resectable disease (T1-3N0, 1M0, UICC clas-
sification, 2002 edition) remains unclear. In addition, a meta-
analysis reported in Australia in 2007 concluded that neoadju-
vant chemoradiotherapy may have additional benefit in cases 
of esophageal adenocarcinoma, but is not effective for patients 
with squamous cell carcinoma, emphasizing the need to choose 
adjuvant therapy according to the histologic type of the disease.
According to the NCCN guidelines, preoperative ther-
apy is indicated for cases with T1b, N1, T2 to resectable 
T4, and resectable Stage IVA disease. Neoadjuvant chem-
otherapy is restricted to cases of adenocarcinoma located 
in the lower esophagus or the esophagogastric junction. 
Lesions in other parts of the esophagus are described as 
indications for neoadjuvant chemoradiotherapy, with the 
recommended drugs specified by category. The England/
Wales and Scotland guidelines do not recommend neoad-
juvant chemoradiotherapy, although they state that adjuvant 
chemotherapy with 2 courses of cisplatin + 5-FU should be 
considered for cases with resectable disease.
Postoperative adjuvant therapy The NCCN guidelines 
recommend postoperative chemotherapy only for patients 
who have received neoadjuvant chemotherapy. Chemora-
diotherapy is recommended for T2-3N0-1 adenocarcinoma 
or N1 adenocarcinoma cases with R0 resection. Some R1–2 
cases may also be included. The Scottish guidelines do not 
recommend either postoperative chemotherapy or chemo-
radiotherapy, based on the results of randomized controlled 
trials for the former and the lack of data for the latter. The 
England/Wales guidelines also do not recommend postop-
erative chemotherapy.
Chemoradiotherapy
With regard to non-surgical treatment, conventional guide-
lines recommend the use of chemoradiotherapy, based 
on reports that chemoradiotherapy yielded better results 
when concurrent chemoradiotherapy was compared with 
radiation monotherapy. According to the 2002 national 
registry of the Japan Esophageal Society, the 5-year sur-
vival rate was 15.1 % in patients who received radiation 
monotherapy, whereas it was 22.9 % in those treated by 
chemoradiotherapy. The corresponding rates by disease 
stage were 32.5 vs. 52.0 % for Stage I–IIA cases and 4.2 
vs. 14.9 % for Stage IIB-IVB cases, indicating the supe-
riority of chemoradiotherapy over radiation monotherapy. 
The protocol recommended by the Radiation Therapy 
Oncology Group that is commonly employed in Europe 
and North America consists of irradiation using the mul-
tiple field technique at a total dose of 50.4 Gy adminis-
tered in 28 fractions, with the exposure field covering 
the region within 5 cm above and below the tumor. This 
regimen is based on the results of a randomized con-
trolled trial that found no difference in the survival period 
between standard-dose (50.4 Gy) and high-dose (64.8 Gy) 
chemoradiotherapy, and reached a negative conclusion 
about the benefit of increasing the total radiation dose. The 
NCCN guidelines specify that the radiation dose should be 
50–50.4 Gy.
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